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3 Summary 
3.1 English Summary 
This work is divided into 3 parts and assesses the association of cardiovascular magnetic 
resonance (CMR)-derived microvascular obstruction (MVO) with readily available biomarkers 
after ST-elevation myocardial infarction (STEMI). 
 CMR allows for a comprehensive assessment of patients with STEMI. Out of a wide 
range of myocardial infarction parameters especially MVO has emerged as a strong predictor 
of adverse outcome in terms of major adverse cardiovascular events and adverse remodeling 
after STEMI. 
 In the first part the association of ST-segment changes, especially the sum of ST-
segment elevation and ST-segment resolution, with MVO is investigated. There was a strong 
relationship of ST-segment changes with the presence of MVO. The sum of ST-segment 
elevation at 90 minutes after reperfusion via primary percutaneous coronary intervention was 
the ECG parameter most strongly associate with MVO. 
 The second part of this work investigates the association of cardiac necrosis markers, in 
detail troponin, creatine kinase and myoglobin, with the occurrence of MVO after STEMI. We 
found a larger release of cardiac necrosis markers in patients with MVO. Troponin was the 
cardiac necrosis marker, which possessed the strongest predictive capability for MVO. 
 Finally, we sought to determine the predictive value of parameters available on patient 
admission for the prediction of MVO in STEMI. A simple score was constructed using only 
clinical and ECG variables, which are the timeliest available variables, on patient admission. 
  10 
3.2 Resumen castellano 
Este trabajo, que se dividió en tres partes, pretendió determinar la asociación entre la 
obstrucción microvascular (MVO) estimada mediante resonancia magnética cardiaca (RMC) 
con determinados marcadores ampliamente disponibles en el contexto del infarto agudo de 
miocardio con elevación del segmento-ST (IAMCEST). 
La RMC permite una exhaustiva evaluación de los pacientes con IAMCEST. En este 
sentido, la aparición de MVO ha mostrado ser un factor asociado a episodios cardiovasculares 
adversos mayores y remodelado negativo tras un IAMCEST. 
En la primera parte de este trabajo, pretendimos explorar la asociación entre el 
sumatorio de las derivaciones con ST elevado (sum-ST) y la resolución del segmento ST con la 
presencia de MVO.  Se observó que el sum-ST determinado a los 90 minutos tras la reperfusión 
mediante angioplastia primaria fue el parámetro más intensamente asociado a la MVO.  
En una segunda etapa, determinamos la asociación entre la liberación de los marcadores 
de necrosis miocárdica (troponina, creatin kinasa y mioglobina) con la aparición de MVO tras 
un IAMCEST.  Con respecto a este punto, observamos una mayor liberación plasmática de 
marcadores de necrosis en los pacientes con MVO; concretamente, la troponina fue el marcador 
que mas inmensamente asociado a la MVO. 
Finalmente, pretendimos evaluar el valor de parámetros clínicos habituales determinados al 
ingreso para predecir MVO. Así, desarrollamos una puntuación simple de riesgo que incluyó 
variables clínicas y electrocardiográficas, todas ellas de fácil adquisición en el momento del 
ingreso.  
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4 Introduction 
In ST-segment elevation myocardial infarction (STEMI) timely reperfusion of the infarct 
related artery by means of percutaneous coronary intervention (PCI) or thrombolysis is the 
primary therapeutic goal the primary therapeutic in order to restore of tissue perfusion (1-3). 
Nevertheless, despite of a patent infarct related artery reperfusion at the microvascular level is 
not always achieved, a phenomenon referred to as microvascular obstruction (MVO) (4). In 
patients with an open infarct-related artery, a lack of reperfusion at the microvascular level has 
been related to worse outcome (1; 2; 5; 6). 
 CMR has become the gold standard in cardiovascular imaging and allows for a 
comprehensive assessment of a wide range of parameters in patients with STEMI (5), including 
infarct size and MVO (4; 7). MVO appears as dark areas within the core of the infarct zone and 
is believed to result from impaired microvascular perfusion due to multifactorial causes 
including edema, microembolization and inflammatory response (8; 9). The presence of MVO 
on CMR imaging has been shown to predict less functional recovery (10)and post infarction 
complications independent of infarct size (11). Moreover the presence of MVO on CMR has 
been associated with worse outcome and left ventricular remodelling compared to non-MVO 
infarctions (7; 11-13). 
Apart from these sequences, using cine sequences, CMR allows for the analysis of 
myocardial mass, volumes and segmental wall thickening and has emerged as the gold standard 
for these purposes (14). 
 Finally, CMR allows for an exact delineation of infarct size and mass in late gadolinium 
enhancement (LGE) sequences (15). The multitude of CMR-derived parameters of myocardial 
infarction is summarized in figure 1. 
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Fig. 1 - Summary of CMR-derived parameters after ST-elevation myocardial  
 
Out of this multitude of CMR-derived infarct parameters, especially MVO has shown to be 
associated with outcome after STEMI. 
We hypothesized that biomarkers as the ECG and cardiac necrosis markers might show a 
significant association with MVO. Therefore the aim of this work was to investigate the 
association of CMR-derived MVO with readily accessible biomarkers after STEMI and to 
determine their predictive value. 
Firstly, the electrocardiogram represents a useful tool, which is virtually omnipresent in 
the clinical environment. Monitoring of ST-segment changes, especially ST-segment resolution 
(STR), has been employed in the past as a simple measure of epicardial reperfusion quality in 
STEMI (16). So far the relationship between ST-segment changes and CMR-derived measures 
of MVO remains to be clarified. The first part of this work aims to analyze the usefulness of 
STR and the extent of the sum of ST-segment elevation (sumSTE) for detecting CMR-derived 
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MVO in a consecutive group of patients with STEMI treated with primary percutaneous 
coronary intervention and re-established blood flow the infarct related artery. 
Secondly, Cardiac necrosis markers, especially troponin quantification, have been 
incorporated into daily practice for diagnostic and risk stratification purposes (17-20). In non-
ST-elevation myocardial infarction, worse prognosis of troponin-positive patients seems to be 
related to the presence of coronary thrombi and microvascular embolization (21; 22). 
Classically, a larger and faster release of cardiac necrosis markers has been considered an 
indicator of successfully recovered epicardial coronary flow (23; 24) and the close relationship 
between troponin release and infarct size has been well established (25). Nevertheless, the 
relationship between the temporal evolution of cardiac necrosis marker release and reperfusion 
at the microvascular level is unknown. Moreover, a simultaneous assessment of the relationship 
of the 3 most widely used necrosis markers, namely troponin, creatine kinase MB mass (CK-
MB) and myoglobin, with the state of microvasculature after reperfused STEMI has not been 
performed so far. 
Finally, we aimed to investigate the capability of clinical parameters and the biomarkers 
already available (including ECG parameters and cardiac necrosis markers) on patient 
admission for prediction of MVO. The prediction of MVO at such a pivotal time point for 
therapeutic decision making has not been attempted before and is desirable since it bears the 
potential of early risk stratification and might have therapeutic implications for therapies 
aiming at the reduction of MVO before reperfusion therapy is initiated. 
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4.1 Original Contribution of the Author 
The author of this work has performed data acquisition and analysis. All three parts of this 
cumulative international thesis have been published in international peer reviewed journals 
endorsed with an impact factor. The author of this work has written all articles and features as 
the first author.  
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5 Materials and Methods 
5.1 Patients and CMR Protocol 
The methodology of this work and the characteristics of the patient population can be consulted 
in detail in the attached published manuscripts. In short, the materials and methods used in all 
parts of this work are displayed here, while individual methods relevant for parts of the work 
are exposed in the respective parts. 
 We prospectively included consecutive patients admitted with a first STEMI. The 
Reperfusion strategy and medical treatment were left to the discretion of the attending 
cardiologists. A pharmacoinvasive strategy (26) consisting of thrombolysis with timely 
angiography or primary PCI were used. A minority of patients did not receive timely 
reperfusion therapy (within 12 hours of symptom onset). 
 Patients underwent CMR (1.5-T, Sonata Magnetom, Siemens, Erlangen, Germany) at 1 
week and, in order to evaluate LV remodeling, at 6 months after STEMI according to our 
laboratory protocol (6; 27). 
 All images were acquired by a phased-array body surface coil during breath-holds and 
were ECG-triggered. First, we obtained cine images. Then, first pass perfusion imaging was 
performed administering 0.1 mmol/kg of gadoliniumdiethylenetriaminepentaacetic acid 
(Magnograf, Juste S.A.Q.F., Madrid, Spain). LGE imaging was performed at least 10 min after 
contrast administration. 
5.2 CMR Analysis 
CMR studies were analysed offline by an experienced observer blinded to all patient data using 
customized software (QMASS MR 6.1.5, Medis, Leiden, The Netherlands). The 17-segment 
model, excluding the apex, was applied (28). 
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Fig. 2 - The 17-segment model for segmental evaluation of myocardial infarction 
parameters (28). 
 
LV ejection fraction (%), end-diastolic and end-systolic volume indexes (ml/m2) and mass 
(g/m²) were calculated by manual planimetry of endocardial and epicardial borders in all short-
axis views cine images. 
 LGE was considered present if signal intensity was >2 standard deviations with respect 
to a remote non-infarcted area in LGE imaging (6). Infarct size was calculated as the 
percentage of LV mass showing LGE. Additionally, the number of segments showing 
transmural (>50% of wall thickness) was calculated. 
 MVO was visually defined on a segmental basis as a lack of contrast uptake in the core 
of a segment surrounded by tissue showing LGE. On a patient basis, significant MVO was 
considered if it was detected in more than one segment (figure 3). 
 The intraobserver variability for the determination these CMR parameters in our group 
is less than 5% (29; 30). 
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Fig. 3 - Short-axis view of late enhancement imaging in two patients with anterior 
infarction of comparable size. Left: Normal contrast uptake in the infarcted zone. Right: 
Lack of contrast uptake in the core of the infarcted area indicating microvascular 
obstruction (arrow). 
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6 Results 
6.1  Sum of ST-Segment Elevation Best Predicts Microvascular Obstruction in 
Patients Successfully Treated with Primary Percutaneous Coronary 
Intervention – A Cardiovascular Magnetic Resonance Study. (Appendix 1) 
Aim: We aimed to analyze the usefulness of ST-segment resolution (STR) and of the extent of 
summatory ST-Segment elevation (sumSTE) for detecting CMR-derived MVO in a 
consecutive group of patients with STEMI treated with primary percutaneous coronary 
intervention and re-established TIMI flow grade III in the infarct related artery. 
Methods: We studied 52 consecutive patients admitted for a first STEMI treated with primary 
PCI and a patent infarct related artery represented by TIMI flow grade 3. A 12-lead ECG was 
recorded on admission and at 90 minutes, 6, 24, 48 and 96 hours after PCI. STR and the sum of 
ST-elevation (sumSTE) in all leads were calculated. 
Results: CMR imaging was performed 9±6 days after primary percutaneous coronary 
intervention. MVO was present in 21 patients (40%). On CMR imaging, MVO was present in 
21 patients. Patients with MVO-infarctions tended to be younger (56 ± 13 years vs. 61 ± 11 
years, p=.167) and had more anterior infarctions (76% vs. 36%, p=.004), a lower systolic blood 
pressure (113 ± 23 mmHg vs. 128 ± 23 mmHg, p=.031) and a larger median peak creatine 
kinase MB (432 ng/ml (364) vs. 97 ng/ml (198), p<.0001).  
 In MVO-infarctions, the extent of sumSTE was significantly larger before and at all 
times after revascularization compared to non-MVO infarctions (p<.03 at all times). In patients 
with MVO-infarctions, the median sumSTE at 24 hours after revascularisation smoothly 
reached 4 mm and did not drop further during the following measurements. In patients without 
MVO the median sumSTE at 96 hours reached 0 mm (figure 4a). In contrast, there was only a 
weak difference in the amount of STR between MVO and non-MVO infarctions (p= ns at all 
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times) albeit with a certain, non-significant, trend to a larger median amount of STR in patients 
without MVO-infarctions (figure 4b). 
 
Fig. 4 - Time course of summatory ST-Segment elevation (left panel) and ST-Segment 
resolution (right panel) according to the presence of MVO on CMR. 
 
As a continuous variable, the extent of sumSTE at all times correlated with the number of 
segments showing MVO on CMR (Spearman's rho = .360 to .413, p.≤01 at all times) while 
there was a weak, non significant correlation between STR and extent of MVO (Spearman's rho 
= -.254 to -.197, p=ns at all times). 
 A multivariate logistic regression model for predicting MVO, adjusted for those 
variables showing a p-value <0.1 in the univariate analyses, was performed. The variables 
included were: systolic blood pressure, anterior infarction, peak creatine kinase MB and 
sumSTE and STR at all time points. SumSTE at 90 min after percutaneous coronary 
intervention was the only parameter associated with the presence of MVO on CMR imaging 
(OR 1.3 95%CI [1.1-1.6], per millimeter, p=.008.)  
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6.2 Release of Necrosis Markers and Cardiovascular Magnetic Resonance-derived 
Microvascular Perfusion in Reperfused ST-Elevation Myocardial Infarction. 
(Appendix 2) 
Aim: We analyzed the association of the dynamics of troponin, creatine kinase MB (CK-MB) 
and myoglobin release with CMR-derived abnormal microvascular perfusion after STEMI. 
Methods: We studied 163 patients with a first ST-elevation myocardial infarction and a patent 
infarct-related artery treated with thrombolysis (67%) or primary angioplasty (33%). Using 
first-pass perfusion CMR, abnormal perfusion (MVO) was defined as a lack of contrast arrival 
into the infarct area in >1 segment. Troponin I, creatine kinase MB and myoglobin were 
measured upon arrival and at 6, 12, 24, 48 and 96 hours after reperfusion. 
Results: Abnormal perfusion was detected in 75 patients (46%). Abnormal perfusion related to 
a larger release of all three cardiac necrosis markers after reperfusion and higher peak values 
(figure 5). The most significant differences were detected in all cases at 6 hours post-
reperfusion. Out of the 3 markers, troponin levels at 6 hours after reperfusion yielded the 
largest area under the receiver operating characteristic curve for prediction of abnormal 
perfusion (troponin: 0.69, creatine kinase MB: 0.65 and myoglobin: 0.58). Patients were 
categorized according to the median troponin level at 6 hours after reperfusion (lower troponin 
0-42 ng/ml and high troponin >42 ng/ml). Abnormal perfusion was more frequent in patients 
with high troponin levels (50/81 (62%) vs. 25/82 (31%), p<.0001).  
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Fig. 5 - Evolution of necrosis marker release depending on the presence of abnormal 
perfusion. 
 
In a comprehensive multivariate analysis, adjusted for clinical, angiographic, cardiovascular 
magnetic resonance parameters and all necrosis markers, high troponin levels at 6 hours after 
reperfusion (>median) independently predicted abnormal microvascular perfusion (OR 2.6 
95%CI [1.2 - 5.5], p=.012). 
 Patients with elevated troponin at 6 hours after reperfusion showed larger infarctions. 
To verify that the association between troponin release and abnormal perfusion was not a mere 
consequence of a larger infarct size or delayed presentation the following analyses were 
performed: 
The whole group was categorized according to the median of infarct size (small infarct: 
≤34% of left ventricular mass vs. large infarct: >34% of left ventricular mass). Abnormal 
perfusion was more frequent in patients with high troponin at 6 hours after reperfusion 
regardless of infarct size: small infarct, 13/31 (42%) vs. 9/50 (18%), p=.019; large infarct, 
37/50 (74%) vs. 16/32 (50%), p=.027. 
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Upon arrival, 72 patients (44%) displayed normal troponin values (<.1 ng/ml). As in the whole 
group, abnormal perfusion was more frequent in the case of high troponin at 6 hours after 
reperfusion: 19/35 (54%) vs. 11/37 (30%), p=.035. 
A multivariate analysis to identify predictors of high troponin levels at 6 hours after 
reperfusion was performed including variables showing a p-value <.1 in the univariate analysis: 
heart rate, anterior infarction, ST-segment resolution ≥70%, rescue angioplasty, proximal left 
anterior descending lesion and all CMR variables. Time to reperfusion was also included. 
Abnormal perfusion (OR 1.23, 95%CI [1.03-1.48], per segment, p=.021), ejection fraction (OR 
.96, 95%CI [.93-.1] per 1% increase, p=.009) and ST-segment resolution ≥70% (OR 0.44 
95%CI [.19-.99], p=.048) were predictors of high troponin levels at 6 hours after reperfusion. 
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6.3 Predictors of Cardiovascular Magnetic Resonance-derived Microvascular 
Obstruction on Patient Admission in STEMI (Appendix 3) 
Aim: We hypothesized that characteristics available on admission would be useful for very 
early prediction MVO-infarction. For this purpose we analyzed the value of clinical and 
electrocardiographic, laboratory and angiographic characteristics, available on patient 
admission in STEMI in the order as the information is available to the clinician, for 
determination of the best and earliest predictors of MVO in patients with STEMI referred for 
primary PCI. 
Methods: Characteristics available on admission were documented in 97 STEMI patients 
referred for primary PCI and their association with CMR-derived MVO was assessed. 
Results: CMR was performed 8±5 days after PCI. MVO was present in 44 patients (45%). 
Patients with MVO-infarctions had a lower left ventricular ejection fraction (43%±12 vs. 
59±11, p<.0001), a larger infarct size (37%±22 vs. 11±10, p<.0001) and more dilated left 
ventricular volumes and masses. 
First the individual value of parameters on patient admission for predicting MVO was 
assessed. Clinical variables on admission associated with MVO were: younger age (56±13 vs. 
60±13, p=.008), lower systolic blood pressure (120mmHg±25 vs. 132±25, p=.02), diabetes 
(25% vs. 9%, p=.04) and Killip class>1 (23% vs. 2%, p=.002). There was a trend towards a 
higher rate of delayed presentation (>3 hours from pain onset) in patients with MVO-
infarctions (39% vs. 21%, p=.05) The ECG on admission revealed a higher percentage of 
anterior infarctions (68% vs. 34%, p<.0001) and a larger median sumSTE (12mm[7-17] vs. 
6[4.5-10], p<.0001) in patients with MVO infarctions. The C-statistic for predicting MVO of 
clinical and ECG variables on admission was .832 [.742-.901]. 
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Laboratory findings on admission associated with MVO were: higher myoglobin serum levels 
(95ng/ml [45-899] vs. 55 [23-99], p=.003) and higher neutrophil count (10.1 (x1000cells/ml) 
±3.7 vs. 8.4±3.7, p=.03). The C-statistic for predicting MVO of laboratory findings on 
admission was .743 [.643-.826]. 
The only angiographic parameter significantly associated with MVO was involvement 
of the proximal left anterior descending artery (43% vs. 17%, p=.005). The C-statistic for 
predicting MVO of angiographic variables was .669 [.566-.762]. Clinical, ECG, laboratory and 
angiographic variables according to the presence of MVO are displayed in table 1. The C-
statistics are displayed in figure 6. 
 
Fig. 6 - Individual diagnostic value of parameters for predicting MVO 
 
The incremental value of parameters for predicting MVO in the order of temporal availability 
was analyzed. The C-statistic of clinical and ECG characteristics (model 1) did not improve 
significantly after adding laboratory information (model 2) (.873 [.789-.932] vs. .832 [.742-
.901], p=.2). Further addition of angiographic findings (model 3: 904 [.827- 
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Fig. 7 - Incremental diagnostic value for predicting MVO 
 
.955]) significantly improved the C-statistic compared to model 1 (p=.04) but not compared to 
model 2 (p=.2) (see figure 7). 
Clinical and ECG characteristics, the parameters most timely available on patient admission, 
displayed a high predictive value for MVO, which was only significantly improved by the 
addition of both laboratory and angiographic data. Owing to this finding, a multivariate 
analysis to identify predictors of MVO from clinical and ECG parameters was performed. 
Independent predictors of MVO were: Killip class>1 (OR 15.97 95%CI [1.37-186.76], p=.03), 
diabetes (OR 6.15 95%CI [1.49-25.39], p=.01), age <55 years (OR 4.70 95%CI [1.56-14.17], 
p=.006), sumSTE>10mm (OR 4.5 95%CI [1.58-12.69], p=.005) and delayed presentation (OR 
3.80 95%CI [1.19-12.1], p=.02). Low blood pressure on admission was not included in this 
analysis since Killip class already accounts for cardiogenic shock. The C-statistic for predicting 
MVO of the model using these variables was .846 [.758-.912], which was not inferior to any of 
the 3 models (p-value between .2-.8).  
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In order to allow for our findings to be integrated into clinical practice a predictive score was 
developed. According to the ORs obtained we created a 4 level score depending on the 
presence of each index. Killip class>1 was assigned 2 points and the remaining indexes 1 point. 
The sum was calculated for each patient and patients were categorized into 4 groups (0 points, 
1 point, 2 points and 3+ points). The C-statistic for predicting MVO using this score was 0.845 
[0.756-0.911], which was not inferior to any of the 3 models (p-value between .1-.9). The 
incidence of MVO gradually increased as the score increased: 0 points: 2 of 23 (8.7%); 1 point: 
9 of 32 (28.1%); 2 points: 20 of 28 (71.4%) and 3+ points: 13 of 14 (93%) (p<.0001 for the 
trend, figure 8). In parallel, the extent of MVO (number of segment with MVO) gradually 
increased with each step of the score (p for the trend <.0001, figure 9). Finally, in order to 
assess the value of the constructed score, we performed a comparison of the new predictive 
score with established markers of MVO.  
Patients with MVO infarctions had a higher TIMI risk score than patients without MVO 
(3.3±2.2 vs. 2.2±1.9, p=.004), nevertheless the C-statistic of the TIMI risk score to predict 
MVO was significantly lower compared to the newly developed score (.658 vs. .839, p=.004).  
The C-statistic of the newly developed score was compared with other, less timely 
available, markers of MVO, namely peak troponin and residual ST-segment elevation. 
Additionally, the score was compared to angiographic surrogates of MVO after PCI: TIMI flow 
grade, corrected TIMI frame count and myocardial blush grade (figure x). The newly 
developed score performed comparable to peak troponin (p=.6) and was superior to residual 
ST-elevation (p=.01) and any of the angiographic parameters (p<.01).  
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Fig. 8 - Prevalence of MVO at each step of the score 
 
Fig. 9 - Extent of MVO at each step of the score 
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Fig. 10 - Comparison of the predictive score with established markers of MVO 
  
  29 
7 Discussion 
7.1 The Impact of MVO after STEMI 
As exposed in the introduction of this work, the paramount importance of microcirculation after 
myocardial infarction has been known for over a decade (1; 2). Despite restored epicardial 
blood flow in STEMI, MVO occurs in about 40% of the cases (11; 12). It has been 
demonstrated that patients with MVO-infarctions have poor recovery of left ventricular 
function and are at high risk for the development of heart failure and death (12). Several non-
invasive and invasive indexes such as angiographic parameters (31; 32), myocardial contrast 
echocardiography (12; 33) or scintigraphy (34) have been used for evaluation of MVO. 
CMR has become the gold standard in cardiovascular imaging and allows for a 
comprehensive assessment of a wide range of parameters in patients with STEMI (5), including 
infarct size and MVO (4; 7). The presence of MVO on CMR imaging has been shown to 
predict less functional recovery (10)and post infarction complications independent of infarct 
size (11). Moreover the presence of MVO on CMR has been associated with worse outcome 
and left ventricular remodelling compared to non-MVO infarctions. (7; 12). 
7.2 ST-Segment Analysis for the Assessment of MVO  
7.2.1 Role of ST-Segment Resolution 
The ECG, as a widely available, rapid and simple method, has been applied as a tool for 
assessing the success of reperfusion therapy in thrombolysis (35). STR has shown to be useful 
for predicting the patency of the infarct related artery. However, its relationship to perfusion at 
the microcirculatory level remains unclear. Several studies investigating microvascular 
perfusion assessed by means of myocardial contrast echocardiography or angiographic blush 
scores have shown that a lack of STR is indicative of MVO (36-38). 
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The relationship between STR and MVO, as derived by a state-of-the-art CMR study, has been 
barely explored in STEMI patients with a patent infarct related artery. Moreover, the existing 
data on the association of CMR-derived MVO with STR is conflicting (31; 32; 39). In the 
present series of patients, we only detected a weak association of STR with MVO. A possible 
explanation for this finding is that STR is a frequent observation after successful primary 
percutaneous coronary intervention and a progressive increase in the amount of STR occurred 
in all patients regardless of the presence of MVO. 
7.2.2 Sum of ST-Segment Elevation and MVO 
A persistence of sumSTE after successful primary percutaneous coronary intervention has been 
linked to microvascular damage assessed by myocardial contrast echocardiography (40). 
Further, it has been shown that a persistent ST-Segment deviation after revascularization yields 
prognostic information after STEMI (41; 42). To the extent of our knowledge, there is no study 
investigating the value of sumSTE for the detection of CMR-derived MVO. In the present 
study, SumSTE was significantly larger throughout all measurements in patients with MVO-
infarction and the extent of sumSTE related to a larger extent of MVO. Additionally, SumSTE 
at 90 min after percutaneous coronary intervention was the only parameter that predicted the 
presence of MVO even after adjustment for clinical, angiographic and other 
electrocardiographic parameters. Each millimeter of remaining sumSTE at 90 min after primary 
PCI increased the probability of MVO by 30%. 
One drawback for the usage of STR as a perfusion marker is that STR highly depends on 
preprocedural extent of sumSTE (43). As a relative measure, STR reflects resolution of the 
initial sumSTE and does not take into account the absolute extent of sumSTE neither on 
admission nor after primary percutaneous coronary intervention. Therefore STR does not 
incorporate the remaining microvascular injury after revascularization. In the present study we 
found a tendency towards a progressive STR in all patients and there was no significant 
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difference between MVO and non-MVO-infarctions, pointing to the low discriminative power 
of this index. For example, a patient who displays complete STR might still have a significant 
amount of sumSTE after percutaneous coronary intervention and thus have a higher probability 
of MVO. 
The dynamic behavior of myocardial microcirculation within the first days and month 
after STEMI has been demonstrated (27). These dynamic changes in abnormal perfusion are 
likely reflected by the smooth normalization in the extent of sumSTE observed in our study. 
This advocates the ECG as the ideal non-invasive tool for assessing the status of the 
microcirculation in the first phase after STEMI and highlights the value of serial 
electrocardiographic examinations after STEMI since the behaviour of the microcirculation, 
mirrored by ST-segment changes, displays marked differences between patients with MVO and 
without MVO. The information about the status of the microcirculation after successful 
primary PCI yielded by the surface ECG was greatest shortly after the procedure at a time point 
when this information is most appreciated by the clinician. 
7.3 The Role of Cardiac Necrosis Markers in MVO 
7.3.1 Necrosis Markers and Abnormal Perfusion 
Studies from the past two decades have demonstrated that successful epicardial reperfusion is 
related to a larger release of cardiac necrosis markers with a steeper increase and wash-out (23; 
24; 44; 45). Currently, the conclusions of these works remain entirely valid, however in STEMI 
the attention has shifted from the macro- to the microcirculation (1; 2). At the time these 
previous studies were performed, the available imaging modalities for the assessment of the 
microcirculation had not been well developed. Today, with CMR, more accurate instruments 
are available, meriting further investigation of the association of cardiac necrosis marker 
release with microvascular perfusion. 
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In the present work, although each of the 3 necrosis markers showed a relationship with MVO, 
the association was strongest with troponin. In non-STEMI, adverse outcome of patients with 
elevated troponin levels seems to result from the presence of fissured plaques, coronary 
thrombi and micro-embolization (21; 22). On the basis of this data one could speculate that, at 
the microvascular level, high troponin elevations relate to impaired rather than successful 
reperfusion. We aimed to validate this hypothesis in the scenario of STEMI in which the 
amount of necrosis and microvascular damage is much larger than in non-STEMI. 
Performing serial measurements of cardiac necrosis markers, we found that patients 
showing MVO on CMR imaging displayed a significantly larger release of necrosis markers 
with peak values at around 6 hours after reperfusion. These results were consistent in the whole 
group and separately in the thrombolysis and primary PCI subgroup. 
Interestingly, the differences in necrosis marker release between patients with and without 
MVO were more pronounced in primary PCI. Contrary to thrombolysis, where timing and 
amount of epicardial flow restoration is less clear, primary PCI represents the perfect scenario 
to assess the relationship between necrosis marker release and microcirculatory damage since 
coronary blood flow was completely and rapidly restored in all patients. In the adjusted 
multivariate analysis, high troponin at 6 hours after successful PCI was a strong predictor of 
MVO. 
These findings likely reflect that in some patients, despite of full recovery of TIMI 3 
flow in the epicardial artery, massive downstream embolization provokes severe abnormal 
perfusion, large infarctions and consequently higher elevations of necrosis markers. 
Of all cardiac necrosis markers, Troponin most closely related to MVO, consistently in 
the whole group, as well as in the subgroups treated with primary PCI and thrombolysis. 
Additionally, a larger CK-MB and myoglobin release also related to MVO. Both markers have 
been classically used for the detection of myocardial infarction (46). Myoglobin allows for a 
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very early detection of myocardial necrosis with limitations due to poor specificity. CK-MB, 
because of its faster kinetics, is a traditional marker of re-infarction (47). In the present study, 
CK-MB and myoglobin levels follow the same course as troponin values, but in the 
multivariate analysis did not enter as independent predictors of abnormal perfusion. 
Elevated troponin and CK-MB after angioplasty yield prognostic information and predict 
adverse outcome (48; 49). Our present study, in the setting of reperfused STEMI, confirms the 
link between elevated biomarkers and MVO previously described in non-STEMI (50). 
7.3.2 Independent Association of Troponin Release with MVO 
The close relationship between troponin release and infarct size has been well established (25). 
Accordingly, we observed that patients with higher troponin values displayed larger infarctions. 
Nevertheless, MVO was more frequent in patients with higher troponin levels regardless of 
infarct size, indicating that the association of troponin release with MVO was not a mere 
consequence of infarct size. Moreover, in a multivariate analysis adjusted for infarct size, the 
extent of MVO persisted as an independent predictor of high serum troponin levels. 
Delayed presentation and consequently delayed reperfusion might provoke larger 
infarcts and wider perfusion deficits (18). Thus, elevated troponin levels detected in patients 
with MVO might originate from delayed reperfusion. Nevertheless, the association of elevated 
troponin with MVO persisted in patients undergoing early reperfusion (with normal troponin 
values immediately before reperfusion) and was even stronger in patients with an early and 
complete coronary flow restoration via primary angioplasty, suggesting a direct connection of 
MVO with a larger troponin release. 
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7.4 Prediction of MVO on Patient Admission 
7.4.1 Clinical Characteristics on Admission and MVO 
Data on how patients with MVO-infarctions initially present is scarce since most studies have 
focused on prediction of MVO after reperfusion therapy and the prognostic impact of MVO. 
We determined the individual value of baseline characteristics in the order as they are available 
on patient admission for predicting the presence of MVO in CMR study performed at 1 week 
after STEMI in a large cohort of STEMI patients referred for primary PCI. An interesting 
finding is that clinical characteristics alone already exhibited a high predictive value for MVO. 
This predictive capability was only significantly improved using the combination of all 
diagnostic domains (i.e. electrocardiographic, laboratory and angiographic data). Of clinical 
parameters, Killip class was identified as the strongest predictor of MVO. Only one patient 
with Killip class >1 on admission did not develop MVO. High Killip class has been shown to 
be an independent predictor of failure to restore TIMI 3 flow in the epicardial coronary artery 
after STEMI (10). In our study we did not confirm this finding (TIMI 3 flow in patients with 
Killip >1: 82%), but there was a strong association with the development of MVO. This finding 
might partly explain the worse prognosis of patients with a high Killip class by linking it to the 
development of MVO, which in turn exhibits a strong negative impact on prognosis (7; 13). 
In the present study patients with MVO-infarction were younger and there was a trend 
towards delayed presentation. The observation that young age associates with MVO has not 
been reported before. Smaller studies in that area did not show a significant age difference 
between patients with MVO and non-MVO-infarctions (51). A possible explanation for this 
finding might be that younger patients might have less ischemic preconditioning and less 
collateral circulation compared to older patients which potentially aggravates myocardial 
damage during coronary occlusion in STEMI. 
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Patients who developed MVO-infarctions had a trend towards a higher rate of delayed 
presentation. This is in line with previous studies demonstrating that MVO strongly depends on 
the duration of the ischemic time (52; 53). 
7.4.2 Biomarkers of MVO on Admission 
The association of CMR-derived MVO with biomarkers like the ECG, cardiac necrosis markers 
and leucocytes has been investigated in the past. Of ECG parameters, as shown in the present 
work, the amount of residual sumSTE after successful primary PCI is a strong predictor of 
MVO and also predicts myocardial salvage (54; 55). We confirmed this finding in the present 
study by demonstrating the high predictive value of ECG data for MVO already on admission. 
As is also shown in the present work, a larger release of cardiac necrosis markers, 
especially troponin, after successfully reperfused STEMI is associated with MVO. Since 
troponin values can be normal or low on admission in STEMI, we did not find a significant 
association of troponin on admission with MVO in the present study. However, due to its faster 
kinetics, myoglobin was significantly higher in patients developing MVO. Nevertheless, the 
use of biomarkers for early risk stratification and decision making is somewhat limited due to 
the inherent time delay in their use. 
Additionally, post-interventional lymphopenia has been linked to a larger amount of 
MVO in reperfused STEMI (56). The present study shows that on admission, there is only a 
trend towards a lower lymphocyte count in patients with MVO infarctions, but neutrophil count 
was significantly higher. 
7.4.3 Angiographic Parameters and MVO 
Angiographic parameters have been used in the past for the evaluation of microvascular 
reperfusion in STEMI.  
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In our study, the only angiographic parameter significantly associated with MVO was the 
involvement of the proximal left anterior descending artery. The lack of association of 
established angiographic parameters like TIMI flow grade, frame count or myocardial blush 
grade might be owed to several reasons. Firstly, the evaluation of the microcirculation by 
angiography is performed at a very early time point and it has been shown that the 
microcirculation display a dynamic behaviour in the first weeks after STEMI (27). Re-
established epicardial blood flow, represented by TIMI 3 flow, is a very specific but not very 
sensitive marker for successful microvascular reperfusion. Accordingly, in our study TIMI 3 
flow was achieved in 91% of patients and there was not a statistical association with MVO. 
Myocardial blush grade, as a good alternative for evaluating microvascular perfusion, displays 
a high interobserver variability. Lastly and a limitation of our study, the evaluation of 
angiographic parameters in a core laboratory might have yielded better results. The addition of 
both laboratory and angiographic parameters to clinical and ECG characteristics improved the 
predictive capacity of the model for MVO, nevertheless the usefulness of angiography for early 
prediction of MVO is limited because the information arrives relatively late for clinical 
decision-making. 
7.4.4 Development of a Predictive Score of MVO on Admission 
The present study is the first to address the problem of MVO in patients with STEMI before 
reperfusion therapy is initiated. A common trait of previous studies investigating predictors of 
MVO is, that they are focused on parameters obtained after the therapeutic intervention had 
been carried out. At that time point the microvascular damage cannot be influenced anymore as 
could be with the use of earlier tools. We identified, from a wide range of clinical and ECG, 
laboratory and angiographic variables available on patient admission independent predictors of 
MVO. We detected that clinical characteristics and ECG data, the two diagnostic domains most 
rapidly available to the clinician on patient admission, yielded a predictive value that was only 
  37 
improved by the addition of both laboratory and angiographic parameters. In order to facilitate 
the integration of this finding into clinical practice we devised a simple predictive score 
according to the presence of 5 indexes (Killip class >1, age<55, diabetes, delayed presentation 
and sumSTE>10mm). This score allowed for the classification of patients according to the risk 
for developing MVO after STEMI. The prevalence, ranging from low (8.7%) to high risk 
(93%), as well as the extent of MVO increased with the increasing points of the score. 
Potentially this simple universally available score allows for triage of patients according 
to the risk for developing MVO and might prove useful as a tool for assessing the efficacy of 
future early therapies aiming at the reduction of MVO.  
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8 Final Conclusions 
In the present cumulative work we set out to investigate the relationship of several biomarkers 
with CMR-derived MVO in reperfused STEMI. Firstly, we demonstrate the value of ST-
segment monitoring for the prediction of CMR-derived MVO. MVO was best predicted by the 
extent of sumSTE shortly after revascularization (90 minutes). Therefore, the assessment of 
ST-segment changes should not only involve the evaluation of STR after primary PCI but 
should focus on the remaining sumSTE providing information on the quality of microvascular 
reperfusion after primary PCI as  a simple bedside measure. 
Secondly MVO associates with a larger release of cardiac necrosis markers. Of these, 
troponin resulted as the best necrosis marker for predicting MVO, especially in primary PCI. 
The predictive capacity yielded by troponin is greatest at 6 hours after reperfusion, a time point 
when information on the microcirculatory status after reperfusion is most appreciated by the 
clinician. The assessment of troponin serum levels at that time point might serve as an 
additional diagnostic tool in our armamentarium to identify patients with MVO. 
Finally, we transferred the results of these previous studies and demonstrated that the 
prevalence of MVO after STEMI can be predicted using parameters available on patient 
admission. Clinical characteristics and ECG parameters yielded a high predictive value, which 
was only improved by the addition of both laboratory and angiographic findings. We developed 
a simple score using clinical and ECG characteristics, which allowed for classification of 
patients according to the prevalence and extent of MVO. Given the timely availability this 
score might prove useful for early classification and risk stratification before reperfusion 
therapy is initiated and for assessing the value of future therapies aiming at the reduction of 
MVO in STEMI. 
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Introduction and objectives. The usefulness of ST-
segment elevation resolution (STR) for predicting epicardial 
reperfusion is well established. However, it is still not clear 
how ST-segment changes are related to microvascular 
obstruction (MVO) observed by cardiovascular magnetic 
resonance (CMR) after primary percutaneous coronary 
intervention (pPCI) for ST-segment elevation myocardial 
infarction (STEMI).
Methods. The study involved 85 consecutive patients 
admitted for a first STEMI and treated by pPCI who had 
a patent infarct-related artery. An ECG was recorded on 
admission and 90 min and 6, 24, 48 and 96 h after pPCI. 
Thereafter, STR and the sum of ST-segment elevation 
(sumSTE) in all leads were determined.
Results. Overall, CMR revealed MVO in 37 patients. In 
infarcts with MVO, sumSTE was greater both before and 
after revascularization than in infarcts without MVO (P≤.001 
at all times). In contrast, there was no significant difference 
in the magnitude of STR between infarcts with and 
without MVO 90 min after revascularization (P=.1), though 
there was after 6 h (P<.05 at all times). The area under 
the receiver operating characteristic curve for detecting 
MVO was greater for sumSTE than STR (P<.05 for all 
measurements). On multivariate analysis, after adjusting 
for clinical, angiographic and ECG characteristics, a 
sumSTE >3 mm 90 min after pPCI was an independent 
predictor of MVO on CMR, while an STR ≥70% was not 
(odds ratio=3.1; 95% confidence interval, 1.2-8.4; P=.02).
Conclusions. MVO was associated with a significantly 
increased sumSTE at all times after revascularization. 
The difference in the magnitude of STR between infarcts 
with and without MVO was significant only >6 h after 
revascularization. The best predictor of MVO was a 
sumSTE >3 mm 90 min after pPCI.
Key words: Cardiovascular magnetic resonance. 
Microvascular obstruction. ST-segment resolution. 
Sum of ST-segment elevation. ST-segment elevation 
myocardial infarction.
La suma de la elevación del segmento ST 
predice mejor la obstrucción microvascular 
en pacientes tratados con éxito con una 
intervención coronaria percutánea primaria.  
Un estudio de resonancia magnética 
cardiovascular
Introducción y objetivos. La utilidad de la resolución 
del segmento ST (RST) para la predicción de la reperfu-
sión epicárdica está bien establecida. La asociación de 
los cambios del segmento ST con la obstrucción micro-
vascular (OMV) observada en la resonancia magnética 
cardiovascular (RMC) tras una intervención coronaria 
percutánea primaria (ICPp) en el infarto de miocardio con 
elevación del ST (IMEST) no se ha aclarado todavía.
Métodos. Estudiamos a 85 pacientes consecutivos in-
gresados por un primer IMEST y tratados con una ICPp 
que tenían una arteria relacionada con el infarto permea-
ble. Se registró un ECG al ingreso, tras 90 min y tras 6, 
24, 48 y 96 h de la ICPp. Se calculó la RST y la suma de 
la elevación del ST (sumEST) en todas las derivaciones.
Resultados. La RMC reveló una OMV en 37 pacientes. 
En los infartos con OMV, el valor de la sumEST antes y 
después de la revascularización fue mayor que en los in-
fartos sin OMV (p ≤ 0,001 en todos los casos). En cam-
bio, no hubo diferencias significativas en la cantidad de 
RST entre los infartos con y sin OMV a los 90 min de la 
revascularización (p = 0,1), sino sólo a partir de las 6 h 
(p < 0,05 en todos los casos). El área bajo la curva de 
características operativas del receptor para la detección 
de la OMV fue mayor para la sumEST que para la RST 
(p < 0,05 en todas las determinaciones). En el análisis 
multivariable, ajustado respecto a las características clí-
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We analyzed the usefulness of STR and the extent 
of the sum of ST-segment elevation (sumSTE) for 
detecting CMR-derived MVO in a consecutive 
group of patients with STEMI treated with pPCI 
and re-established TIMI flow grade 3 in the infarct 
related artery.
METHODS
Patients
We prospectively included 100 consecutive 
patients admitted to a university hospital for a first 
STEMI treated with pPCI within 12 hours after the 
onset of chest pain. The inclusion criteria were: a) 
stable clinical course without complications during 
hospitalization; b) no contraindications to CMR; 
and c) TIMI flow grade 3 in the infarct related artery 
after revascularization. We excluded 4 patients 
because of claustrophobia and 7 patients due to TIMI 
flow grade ≤2 after pPCI. Patients with inconclusive 
ECG (bundle branch block or ventricular pacing) 
were excluded (4 cases). Therefore, the final study 
group comprised 85 patients. All patients gave 
written informed consent and the study protocol 
was approved by the local ethics committee.
Percutaneous Coronary Intervention  
and Angiography
pPCI was performed within 12 hours of symptom 
onset in all patients. TIMI flow grade12 before and 
after the procedure was assessed. Myocardial blush 
grade13 was evaluated after pPCI. Angiographic 
data was analyzed by an experienced investigator 
unaware of patient identity, ECG and CMR results 
using standard software (HM3000, Philipps, Best, 
The Netherlands).
ECG Analysis
A standard 12 lead ECG was recorded upon 
admission and at 90 minutes, 6 hours, 24 hours, 48 
hours, and 96 hours after pPCI at a paper speed 
of 25 mm/s and an amplification of 10 mm/mV. 
ECG data was evaluated by an observer unaware 
of patient identity, angiographic data and CMR 
results. The isoelectric line was defined as the level 
of the preceding TP-segment. Extent of ST-segment 
elevation was measured 20 ms after the J-point in 
every lead. The following ECG parameters were 
determined:
– Sum of ST-segment elevation (sumSTE): 
sumSTE was manually calculated as the sum of 
ST-segment elevation in all leads using previously 
validated algorithms as the sum of elevation in V1–6, 
nicas, angiográficas y electrocardiográficas, una sumEST 
> 3 mm a los 90 min de la ICPp, pero no una RST ≥ 70%, 
predijo de manera independiente la OMV observada en 
la RMC (odds ratio = 3,1; intervalo de confianza del 95%, 
1,2-8,4; p = 0,02).
Conclusiones. La OMV se asoció a un valor significa-
tivamente superior de la sumEST en todos los momentos 
de valoración tras la revascularización. La diferencia en 
la cantidad de RST entre los infartos con OMV y sin OMV 
sólo fue significativa a partir de las 6 h tras la revascu-
larización. La OMV se predijo mejor con una sumEST 
> 3 mm a los 90 min de la ICPp.
Palabras clave: Resonancia magnética cardiovascular. 
Obstrucción microvascular. Resolución del segmento ST. 
Suma de la elevación del segmento ST. Infarto de mio-
cardio con elevación del segmento ST.
INTRODUCTION
In ST-segment elevation myocardial infarction 
(STEMI), the timely re-establishment of blood flow 
in the infarct related artery via primary percutaneous 
coronary intervention (pPCI) is crucial. However, 
in spite of Thrombolysis in Myocardial Infarction 
(TIMI) flow grade 3 in the epicardial coronary 
artery, perfusion at tissue level may be impaired; a 
phenomenon referred to as microvascular obstruction 
(MVO). Cardiovascular magnetic resonance (CMR) 
allows for a comprehensive assessment of STEMI 
patients1 with accurate detection of MVO.2,3
Several studies have shown that the presence 
of MVO is associated with adverse outcome, 
unfavourable left ventricular remodelling and higher 
mortality.4-6
Monitoring of ST-segment changes, especially ST-
segment resolution (STR), has been employed in the 
past as a simple measure of epicardial reperfusion 
quality in STEMI.7 Furthermore, STR has been used 
as a surrogate end-point for MVO in the past7,8 but 
the value of STR for detecting CMR-derived MVO 
is conflicting9,10,11 and the relationship between ST-
segment changes and MVO remains to be clarified.
ABBREVIATIONS
CMR: cardiovascular magnetic resonance
MVO: microvascular obstruction
pPCI: primary percutaneous intervention
STEMI: ST-segment elevation myocardial 
infarction
STR: ST-segment elevation resolution
sumSTE: sum of ST-segment elevation
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Microvascular obstruction: on a segmental basis 
MVO was visually defined in late enhancement 
imaging as a lack of contrast uptake in the core 
of a segment surrounded by tissue showing late 
enhancement2 (Figure 1). On a patient basis, 
significant microvascular obstruction was considered 
if it was detected in at least 1 segment. Intraobserver 
variability for the detection of MVO using this 
criterion in our laboratory was 1%.
Statistical Analysis
All data were tested for normal distribution 
using the one-sample Kolmogorov-Smirnov test. 
Continuous normally distributed data were expressed 
as the mean (standard deviation) and compared 
using Student's t test. Non-parametric data were 
expressed as the median with the interquartile range 
(IQR) and were compared with the Mann-Whitney 
U test. Group percentages were compared using the 
c
2 test or Fisher’s exact test where appropriate.
Receiver operating characteristic curve analysis 
for predicting MVO was performed for STR 
and sumSTE at all time points. The areas under 
the receiver operating characteristic curve were 
compared.
In order to determine the predictive value of 
sumSTE and STR, a logistic regression model was 
applied, adjusted by variables showing a P-value 
<.1 in univariate analyses (Table 1). These variables 
were: systolic blood pressure, anterior infarction 
and peak creatine kinase MB. Odds ratios with the 
respective 95% confidence intervals were computed.
Statistical significance was considered for 2-tailed 
P-value <.05. SPSS 13.0 (SPSS Inc, Chicago, Illinois, 
USA) and STATA 9.0 (StataCorp, College Station, 
Texas, USA) were used.
RESULTS
The baseline characteristics and angiographic 
data of all patients are displayed in Table 1. The 
mean age was 60 (13) years (range, 31-90) with the 
majority of the patients being male (81%). Median 
time from pain onset to revascularization was 210 
minutes [141-420]. Abnormal TIMI flow grade (0-2) 
was present in 87% prior to pPCI with an occluded 
infarct related artery in 78% of the cases. A stent was 
placed in 96% of patients and TIMI flow grade 3 in 
the infarct related artery was established in all cases. 
Myocardial blush grade 2-3 was observed in 77% 
after pPCI.
The evolution of sumSTE and STR over time in 
the entire patient population is displayed in Figure 
2. The median sumSTE on arrival was 9.0 mm [6.0-
14.0] and dropped to 3.0 mm [0.0-6.0] after pPCI 
(Figure 2A). Accordingly, the median STR at 90 
I, and aVL for anterior infarction and as the sum of 
elevation in leads II, III, aVF, V5, and V6 for non-
anterior infarction.7,14,15 For dichotomic univariate 
analysis of sumSTE we implemented cut-off values 
established on the basis of the area under the 
receiver operating characteristics curves (AUC) for 
predicting MVO by maximizing the observed overall 
diagnostic accuracy (minimizing the number of false 
positives plus the number of false negatives).
– ST-segment resolution: STR was defined as 
the percent reduction in the sumSTE obtained on 
admission and each time point following pPCI. 
Complete STR was considered for a reduction of 
≥70%.7,15
Cardiovascular Magnetic Resonance Imaging
CMR (1.5-T scanner, Sonata Magnetom, Siemens, 
Erlangen, Germany) was performed at least 48 hours 
after cardiac catheterization in accordance with our 
laboratory protocol.16,17 Images were acquired by a 
phased-array body surface coil during breath-holds 
and were ECG-triggered. Cine images (steady-state 
free precession sequence; repetition time / echo time: 
3.2/1.6 ms, flip angle: 61 degrees, matrix: 256¥128, 
slice thickness: 6 mm, temporal resolution: 26 ms) 
were acquired in 2-, 3-, 4-chamber views and every 1 
cm in short-axis views. 
Late enhancement imaging was performed in 
the same projections used for cine images at least 
10 minutes after administering 0.1 mmol/kg of 
gadolinium-diethylenetriaminepentaacetic acid 
(Magnograf, Juste S.A.Q.F., Madrid, Spain). A 
segmented inversion recovery imaging with steady 
state free precession sequence was used (repetition 
time / echo time: 2.5/1.1 ms, slice thickness: 6 mm, 
flip angle: 50 degrees, matrix: 195¥192) nullifying 
myocardial signal.
Cardiovascular Magnetic Resonance Imaging 
Data analysis
CMR studies were analyzed by an experienced 
observer blinded to all patient, angiographic and 
ECG data using customized software (QMASS MR 
6.1.5, Medis, Leiden, The Netherlands). Segment 
location was defined according to the 17-segment 
model18. Left ventricular mass (g/m²), ejection 
fraction (%), and volumes (mL/m²) were quantified 
by manual definition of endocardial borders of all 
short-axis slices in cine-images. Late gadolinium 
enhancement was considered in the case of signal 
intensity >2 standard deviations with respect to 
a remote non-infarcted area in late gadolinium 
enhancement imaging.16,19 Infarct size was calculated 
as the percentage of left ventricular mass showing 
late gadolinium enhancement.17
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On CMR imaging, patients with MVO-infarctions 
showed a larger infarct size (37 [23%] vs 11 [9]; 
P<.0001), a lower left ventricular ejection fraction 
(44 [13%] vs 59 [12]; P<.0001) and larger end-
systolic (54 [31] mL/m² vs 29 [14]; P<.0001) and 
end-diastolic (93 [33] mL/m² vs 70 [18]; P<.0001) 
left ventricular volumes and mass (81 [19] g/m² vs 65 
[15]; P<.0001).
Relationship of SumSTE and STR With 
Microvascular Obstruction
In MVO-infarctions, the extent of sumSTE was 
significantly larger before and at all time points 
after revascularization compared to non-MVO-
infarctions (P≤.001 at all time points). In patients 
with MVO-infarctions, the median sumSTE at 24 
hours after revascularisation smoothly reached 3 
mm and did not drop further during the following 
measurements. In patients without MVO the 
median sumSTE at 6 hours reached 0 mm 
(Figure 3A). The amount of STR did not differ 
significantly at 90 min after pPCI between MVO 
min after pPCI was 71% [22-100] (Figure 2B). Both 
indexes showed a progressive normalization over 
time. The percentage of patients displaying complete 
STR (≥70%) steadily increased over time (53% at 90 
min, 67% at 6h, 73% at 24h, 74% at 48h, and 77% 
at 96h).
Cardiovascular Magnetic Resonance Imaging 
Results
CMR imaging was performed 6 (2) days after pPCI. 
The clinical course between both examinations was 
stable in all patients. MVO was present in 37 patients 
(44%). Clinical and angiographic characteristics of 
the patients with and without evidence of MVO on 
CMR imaging are displayed in Table 1.
Patients with MVO-infarctions were younger 
(56 [14] years vs 63 [12]; P=.02), had more anterior 
infarctions (68% vs 33%; P=.002), a larger median 
peak creatine kinase MB 334 [162-503] ng/mL vs 85 
[44-197]; P<.0001) and there was a trend towards a 
lower systolic blood pressure (119 [26] mmHg vs 130 
[25]; P=.05).
Figure 1. Coronary angiography and late 
gadolinium enhancement cardiovascular 
magnetic resonance imaging of two 
patients with an anterior myocardial 
infarction. After primary percutaneous 
intervention, TIMI flow grade 3 was 
established in the left anterior descending 
artery (left upper and lower panel). In 
one patient, on cardiovascular magnetic 
resonance imaging (right upper panel), 
late enhancement sequences show a 
large area of transmural necrosis along 
the anteroseptal wall with a lack of 
contrast arrival in the core of the infarcted 
area (arrow). While infarct size was 
comparable, no evidence of microvascular 
obstruction was present in the other 
patient (right lower panel).
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STR (≥70%) at 90 minutes after pPCI is displayed in 
Table 4. SumSTE >3 mm yielded a higher diagnostic 
accuracy for predicting MVO than STR≥70%.
Multivariable Analysis
A multivariate logistic regression model for 
predicting MVO at 90 minutes after pPCI, adjusted 
for those variables showing a P-value <.1 in the 
univariate analyses, was performed. The variables 
included were: age, diabetes, smoker, systolic blood 
pressure, anterior infarction, median peak creatine 
kinase MB, involvement of the proximal left 
anterior descending artery, sumSTE >3 mm at 90 
min and STR ≥70% at 90 min. Anterior infarction 
(OR, 4.2; 95% CI, 1.8-11.2; P=.04) and sumSTE >3 
mm at 90 min after pPCI (OR, 3.1; 95% CI, 1.2-8.4; 
P=.02) were the only parameters associated with the 
presence of MVO on CMR imaging.
DISCUSSION
The main finding of the present study is that 
monitoring of ST-segment characteristics is useful 
for predicting MVO in patients with STEMI treated 
with pPCI and re-established TIMI flow grade 3 in 
the infarct related artery. The amount of SumSTE 
at 90 min after pPCI was shown to be a simple 
and non-MVO infarctions (P=.1). In the following 
measurements patients with non-MVO infarctions 
had a significant larger amount of STR than did 
patients with MVO infarctions (P≤.02 from 6 h to 
96 h) (Figure 3B). 
Table 2 shows the areas under the receiver 
operating characteristic curve of sumSTE and STR 
at all time points for predicting MVO. SumSTE 
yielded a significantly larger area under the curve at 
every measurement compared to the corresponding 
STR at that time point. 
Since STR is habitually dichotomized according 
to complete (≥70%) versus incomplete (<70%) 
the following analyses were carried out: When 
dichotomized according to complete STR (≥70% 
vs <70%) there was no significant difference in 
the prevalence of MVO between the 2 groups at 
90 minutes (36% vs 52%; P=.1). Only from 24 
hours after revascularization onwards, patients 
with complete STR displayed a significantly lower 
prevalence of MVO (Table 3). 
According to the best cut-off derived from the area 
under the receiver operating characteristic curve, 
sumSTE at 90 minutes after pPCI was dichotomized 
(sumSTE ≤3 vs sumSTE >3 mm). Patients with 
sumSTE >3 mm had a higher prevalence of MVO 
than patients with sumSTE ≤3 (63% vs 28%; P=.001). 
The diagnostic accuracy of sumSTE >3 and complete 
TABLE 1. Baseline Characteristics and Angiographic Data
 
Total
 Microvascular Obstruction 
P-Value
  Absent Present
Patients 85 48 37 
Men (%) 69 (81) 40 (83) 29 (78) .6
Age, mean (SD), y 60 (13) 63 (12) 56 (14) .02
Median time to revascularization, min 210 [141-420] 190 [140-326] 240 [145-510] .22
Median peak creatine kinase-MB, ng/mL 299 [62-408] 85 [44-197] 334 [162-503] <.0001
Heart rate, bpm 79 (17) 78 (17) 79 (18) .8
Systolic blood pressure, mm Hg 125 (26) 130 (25) 119 (26) .05
Risk factors    
 Active smoker (%) 44 (52) 21 (44) 23 (62) .09
 Hypertension (%) 40 (47) 22 (46) 18 (49) .8
 Diabetes mellitus (%) 12 (14) 4 (8) 8 (22) .08
 Dyslipidemia (%) 34 (40) 19 (40) 15 (41) .9
Anterior infarction (%) 41 (48) 16 (33) 25 (68) .002
TIMI flow grade 3 before PCI (%) 11 (13) 6 (13) 5 (14) .9
Myocardial blush grade 2-3 after PCI (%) 65 (77) 36 (75) 29 (78) .7
Affection of the proximal LAD (%) 22 (26) 9 (19) 13 (35) .09
Glycoprotein IIb/IIIa inhibitors (%) 53 (62) 28 (58) 25 (68) .4
Stent placement (%) 82 (96) 46 (96) 36 (97) .9
Vessel occulusion prior to PCI (%) 66 (78) 35 (73) 31 (84) .2
Bpm indicates beats per minute; PCI, primary percutaneous intervention; LAD, left anterior descending artery; TIMI, Thrombolysis in Myocardial Infarction.
Values are displayed as the mean (standard deviation) (compared with Student t test), absolute numbers with percentages in parenthesis (compared using c2 test) or the me-
dian with the interquartile range in square parenthesis (compared using the Mann-Whitney U test).
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level can occur, a phenomenon referred to 
as MVO.20,21 It has been demonstrated that 
patients with MVO-infarctions have poor 
recovery of left ventricular function and are 
at high risk for development of heart failure 
and death.20 Several non-invasive and invasive 
indexes such as angiographic parameters,9,10 
predictor of MVO even after adjustment for baseline 
characteristics and angiographic data.
Microvascular Obstruction
In spite of restoration of epicardial blood flow 
in STEMI, impairment at the microvascular 
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Figure 2. A: sum of ST-segment elevation 
(mm).B: extent ST-segment resolution (%) 
on admission and after revascularization 
in the entire group of patients. Data at the 
bottom of the graphs indicate the median 
with the interquartile range.
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ST-Segment Analysis for Assessing 
Microvascular Perfusion. Role of ST-Segment 
Resolution
The ECG, as a widely available, rapid and simple 
method, has been applied as a tool for assessing the 
success of reperfusion after thrombolysis.25 STR 
is useful for predicting the patency of the infarct 
related artery and thus epicardial reperfusion but 
its relationship to perfusion on the microcirculatory 
level remains unclear. Several studies investigating 
microvascular perfusion assessed by myocardial 
contrast echocardiography or angiographic blush 
scores have shown that a lack of STR is indicative 
of MVO.13,14,26
So far, the relationship between STR and CMR-
derived MVO has been barely explored in STEMI 
patients with a patent infarct related artery after 
pPCI and existing data on the association of CMR-
derived MVO with STR is conflicting.9,10,11
Two studies in the past reported no significant 
relationship with STR and CMR-derived MVO.9,10 
While in another study CMR-derived MVO analyzed 
in first pass perfusion and late enhancement was 
related to incomplete STR, defined as ≥70%.11
In our series of patients, there was not a significant 
association of STR with MVO at 90 min after pPCI 
neither as a continuous nor as a binary variable. 
Nevertheless, in the following measurements 
patients with MVO-infarctions displayed a 
significant lower amount of STR that did patients 
without MVO-infarctions. Accordingly, after 24 
hours after revascularization and onwards, patients 
with complete STR (≥70%) had a significantly lower 
prevalence of MVO.
Sum of ST-Segment Elevation and 
Microvascular Obstruction
In the present study, SumSTE was significantly 
larger throughout all measurements in patients with 
MVO-infarctions. When dichotomized (>3 mm vs 
≤3 mm) sumSTE at 90 minutes after pPCI yielded 
a higher diagnostic accuracy for detecting MVO 
than complete STR and accordingly MVO was 
more frequent in patients displaying a high sumSTE 
myocardial contrast echocardiography,20,22 or 
scintigraphy23 have been used for the evaluation 
of MVO.
CMR has become the gold standard in 
cardiovascular imaging and allows for a 
comprehensive assessment of a wide range of 
parameters in patients with STEMI,1 including 
infarct size and MVO.2,3 The presence of MVO 
on CMR imaging has been shown to predict 
less functional recovery24 and post infarction 
complications independent of infarct size.21
TABLE 2. Area Under the Receiver Operating 
Characteristic Curve of ST-Segment Elevation 
and ST-Segment Resolution at All Time Points for 
Predicting Microvascular Obstruction 
Time Sum of ST- ST-Segment  
 Segment Elevation Resolution
 AUC (95%  AUC (95%  P- 
 Confidence Interval) Confidence Interval) Value
Admission 0.728 (0.621 to –0.819)                     –                        –
90 min 0.699 (0.59 to –0.794) 0.602 (0.49 to –0.707) .006
6 h 0.706 (0.597 to –0.8) 0.647 (0.536 to –0.748) .01
24 h 0.704 (0.596 to –0.798) 0.666 (0.555 to –0.764) .048
48 h 0.708 (0.599 to –0.801) 0.665 (0.555 to –0.764) .02
96 h 0.714 (0.605 to –0.807) 0.672 (0.562 to –0.77) .03
AUC indicates area under the receiver operating characteristic curve.
TABLE 3. Prevalence of Microvascular Obstruction 
According to Complete ST-Segment Resolution 
(≥70%) at Every Time Point
Time
 Prevalence of MVO
 STR <70% STR ≥70% 
P-Value
90 min 52% 36% .1
6 h 57% 37% .08
24 h 65% 36% .01
48 h 68% 35% .007
96 h 70% 35% .006
MVO indicates microvascular obstruction; STR, ST-segment resolution.
TABLE 4. Diagnostic Accuracy of Sum of ST-Segment Elevation (>3 mm) and Complete ST-Segment Resolution 
(≥70%) at 90 Minutes After Percutaneous Coronary Intervention for Detecting Microvascular Obstruction
 Sensitivity Specificity PPV NPV Accuracy
sumSTE >3 mm 24/37 (65%) 34/48 (71%) 24/38 (63%) 34/47 (72%) 58/85 (68%)
STR ≥70% 21/37 (57%) 29/48 (60%) 21/40 (53%) 29/45 (64%) 50/85 (59%)
NPV, negative predictive value; PPV, positive predictive value; STR, ST-segment resolution; sumSTE indicates sum of ST-segment elevation.
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on admission yielded the largest AUC for predicting 
MVO. The exact implications of this finding remain 
to be determined.
STR highly depends on pre-procedural extent 
of sumSTE.27 As a relative measure, STR reflects 
(>3 mm)(63% vs 28%; P=.001). In a multivariate 
analysis adjusted for clinical and angiographic 
parameters, the presence of an elevated sumSTE (>3 
mm) at 90 minutes after revascularization was an 
independent predictor of MVO. Of note, sumSTE 
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Figure 3. A: time course of the sum 
of ST-segment elevation (mm). B: ST-
segment resolution (%) according to the 
presence of microvascular obstruction 
on cardiovascular magnetic resonance 
imaging. The sum of ST-segment elevation 
was significantly higher at all time points 
in patients with microvascular obstruction 
(MVO) compared to patients without MVO. 
For ST-segment resolution there was no 
statistically significant difference at the 
first measurement after revascularization 
between the 2 groups. During the 
following measurements patients without 
MVO displayed a significant larger amount 
of STR. Data at the bottom of the graphs 
indicate the median with the interquartile 
range and the P-value for comparison of 
patients with and without MVO.
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that myocardial blush grade was not associated with 
MVO might be that this variable is more operator-
dependent and might have yielded better results if 
evaluated in a core laboratory.
CONCLUSIONS
Our study demonstrates the value of ST-segment 
monitoring for prediction of CMR-derived MVO. 
MVO was best predicted by the extent of sumSTE. 
Therefore, the assessment of ST-segment changes 
should not only involve the evaluation of STR 
after pPCI but should also focus on the remaining 
sumSTE. This simple bedside measure provides 
information on the quality of microvascular 
reperfusion after pPCI.
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Introduction: The association of the temporal evolution of cardiac necrosis marker release with cardiovascular
magnetic resonance-derived microvascular perfusion after ST-elevation myocardial infarction is unknown.
Methods: We analyzed 163 patients with a ﬁrst ST-elevation myocardial infarction and a patent infarct-
related artery treated with thrombolysis (67%) or primary angioplasty (33%). Using ﬁrst-pass perfusion CMR,
abnormal perfusion was deﬁned as a lack of contrast arrival into the infarct area in N1 segment. Troponin I,
creatine kinase MB and myoglobin were measured upon arrival and at 6, 12, 24, 48 and 96 hours after
reperfusion.
Results: Abnormal perfusion was detected in 75 patients (46%) and was associated with a larger release of all
3 necrosis markers after reperfusion and higher peak values. This association was observed in the whole
group and separately in patients treated with thrombolysis and primary angioplasty. Out of the 3 markers,
troponin levels at 6 hours after reperfusion yielded the largest area under the receiver operating
characteristic curve for prediction of abnormal perfusion (troponin: 0.69, creatine kinase MB: 0.65 and
myoglobin: 0.58). In a comprehensive multivariate analysis, adjusted for clinical, angiographic, cardiovas-
cular magnetic resonance parameters and all necrosis markers, high troponin levels at 6 hours after
reperfusion (Nmedian) independently predicted abnormal microvascular perfusion (OR 2.6 95%CI [1.2 - 5.5],
p=.012).
Conclusions: In ST-elevation myocardial infarction, a larger release of cardiac necrosis markers soon after
reperfusion therapy relates to abnormal perfusion. Troponin appears as the most reliable necrosis marker for
an early detection of cardiovascular magnetic resonance-derived abnormal microvascular reperfusion.
© 2009 Elsevier Ltd. All rights reserved.
Introduction
Cardiac necrosis markers, especially troponin quantiﬁcation, have
been incorporated into daily practice for diagnostic and risk stratiﬁca-
tion purposes [1–4]. In non-ST-elevation myocardial infarction, worse
prognosis of troponin-positive patients seems to be related to the
presence of coronary thrombi and microvascular embolization [5,6].
In ST-elevation myocardial infarction (STEMI), the primary ther-
apeutic objective is the restoration of tissue perfusion [7,8]. In patients
with an open infarct-related artery, a lack of reperfusion at the
microvascular level is related to a worse outcome [7–11]. Classically, a
larger and faster release of cardiac necrosis markers has been con-
sidered an indicator of successfully recovered epicardial coronary ﬂow
[12,13] and the close relationship between troponin release and infarct
size has been well established [14]. Nevertheless, the relationship
between the temporal evolution of cardiac necrosismarker release and
reperfusion at the microvascular level is unknown. Moreover, a
simultaneous assessment of the relationship of the 3 most widely
used necrosismarkers, namely troponin, creatine kinaseMBmass (CK-
MB) and myoglobin, with the state of microvasculature after reper-
fused STEMI has not been performed so far.
Cardiovascular magnetic resonance (CMR) allows for a state-of-
the-art analysis of infarct size and microvascular perfusion after myo-
cardial infarction [9,10,15]. We analyzed the association of troponin,
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CK-MB and myoglobin release with CMR-derived abnormal micro-
vascular perfusion after STEMI.
Methods
Patients
We prospectively included 229 consecutive patients admitted
for a ﬁrst STEMI. Inclusion criteria were: Reperfusion therapy within
the ﬁrst 12 hours after chest pain onset, stable clinical course during
the ﬁrst week and no contraindications to CMR. Further, in order to
investigate primary alterations in the microcirculation, only patients
with TIMI 3 ﬂow and no signiﬁcant residual stenosis (b50%) in
the infarct-related artery at the end of cardiac catheterization as well
as TIMI 3 ﬂow in non-related arteries were included. We excluded
66 patients due to: delayed presentation (8 cases), death (12 cases),
re-infarction (8 cases), clinical instability precluding CMR (15 cases),
TIMI ﬂow ≤2 (10 cases), occlusion of non-related arteries (4
cases), angioplasty-related infarction in routine post-thrombolysis
catheterization (deﬁned as N10 ng/ml increase; twice upper limit
of normal for CK-MB; 3 cases), claustrophobia (4 cases) and cardiac
surgery (2 cases). Therefore, the ﬁnal study group included 163
patients.
The local ethics committee approved the research protocol and
informed consent was obtained from all subjects.
Blood samples and cardiac necrosis markers
Troponin I, CK-MB andmyoglobinweremeasured upon arrival and
at 6, 12, 24, 48 and 96 hours after reperfusion.
Troponin I was measured using a highly sensitive immunoassay
(Dimension, Dade Behring Inc., Newark, USA). The coefﬁcient of
variation for troponin values between 0.1 and 1 ng/ml was b10% and
for troponin values N1 ng/ml was b5%.
CK-MB mass and myoglobin (using immunometric assay; DPC; Los
Angeles, CA, USA) were also determined. The coefﬁcients of variation
for CK-MB mass N5 ng/ml and for myoglobin N70 ng/ml were b10%.
Cardiac catheterization
The infarct-related artery was the left anterior descending artery in
89 patients (55%), the right coronary artery in 64 (39%) and the left
circumﬂex artery in 10 (6%).
The reperfusion strategy was left to the discretion of the attending
cardiologists: 109 patients (67%) were treated with thrombolysis and
54 (33%) were directly submitted to percutaneous revascularization.
Time to reperfusion (from chest pain onset) was recorded.
In patients treated with thrombolysis, rescue angioplasty was
carried out within the ﬁrst 3 hours after thrombolytic administration
in 20 patients (18%) with persistent chest pain and ST-segment
resolution b50%. In the remaining 89 patients, cardiac catheterization
was performed at least 24 hours after STEMI (at 3±1 days, range 1-
4 days).
A stent was placed in 147 patients (90%) when luminal narrowing
in the infarct-related artery was N50%: 51 in primary angioplasty, 18 in
rescue angioplasty and 78 in patients treated with thrombolysis in
routine pre-discharge cardiac catheterization.
Fig.1. Short-axis view of ﬁrst-pass perfusion imaging in two patients with anterior infarction. Left: preserved perfusion in the infarcted area (arrow). Right: abnormal perfusion in the
infarcted area (arrow).
Table 1
Characteristics of the whole group and of patients with abnormal perfusion and normal
perfusion.
All patients
(n=163)
Normal
Perfusion
(n=88)
Abnormal
perfusion
(n=75)
p-value
Age (years) 58±12 59±11 58±13 .8
Male sex (%) 141 (87) 75 (85) 66 (88) .6
Diabetes (%) 23 (14) 14 (16) 9 (12) .5
Hypertension (%) 72 (44) 38 (43) 34 (45) .8
Hypercholesterolemia (%) 59 (36) 28 (32) 31 (41) .2
Current smoker (%) 100 (61) 56 (64) 44 (59) .5
Anterior infarction (%) 89 (55) 36 (41) 53 (71) .0001
Heart rate (beats per minute) 80±21 76±19 85±23 .004
Systolic blood pressure (mmHg) 123±26 125±24 121±27 .3
Primary angioplasty (%) 54 (33) 23 (26) 31 (41) .04
Rescue angioplasty (%) 20 (12) 4 (5) 16 (21) .001
Time to reperfusion (minutes) 242±178 218±162 269±194 .07
ST-segment resolution ≥70% (%) 40 (25) 25 (28) 15 (20) .2
Median peak troponin (ng/ml) 78 (62) 56 (62) 91 (42) b .0001
Median peak creatine kinase-MB
(ng/ml)
210 (323) 170 (208) 276 (339) .001
Median peak myoglobin (ng/ml) 655 (1174) 348 (923) 800 (1567) .08
Cardiac catheterization
Proximal left anterior descending (%) 44 (27) 21 (24) 23 (31) .4
Stent (%) 147 (90) 81 (92) 66 (88) .4
Occluded artery pre-angioplasty (%) 59 (36) 22 (25) 37 (49) .001
TIMI 3 ﬂow pre-angioplasty (%) 84 (52) 53 (60) 31 (41) .02
TIMI 3 ﬂow post-angioplasty (%) 163 (100) 88 (100) 75 (100) -
Blush grade 2-3 post-angioplasty (%) 126 (77) 76 (86) 50 (67) .003
Glycoprotein IIb/IIIa inhibitor use (%) 72 (44) 41 (47) 31 (41) .5
Cardiovascular magnetic resonance
Ejection fraction (%) 52±14 57±11 45±13 b .0001
End-diastolic volume (ml/m2) 80±26 75±23 86±29 .01
End-systolic volume (ml/m2) 40±23 33±16 49±27 b .0001
Left ventricular mass (g/m2) 71±20 68±17 75±22 .01
Infarct size (% of left ventricular mass) 32±15 25±13 39±15 b .0001
Abnormal perfusion (segments) 2.1±2.5 .2±.4 4.5±1.9 b .0001
Abbreviations: TIMI=thrombolysis in myocardial infarction.
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TIMI ﬂow grade in the initial and ﬁnal angiographies and
myocardial blush grade after angioplasty were determined ofﬂine by
an experienced observer unaware of CMR results using the software
Integris HM3000 (Philips, Best, The Netherlands). TIMI 3 ﬂow and
myocardial blush grade 2-3 were regarded as normal [16].
CMR
CMR (1.5-T scanner, Sonata Magnetom, Siemens, Erlangen, Ger-
many) was performed 9±6 days (at least 48 hours after cardiac
catheterization) after myocardial infarction in accordance with our
Fig. 2. Evolution of necrosis marker release depending on the presence of abnormal perfusion in thewhole group. Data at the bottom indicate themedianwith the interquartile range
of troponin over time according to normal or abnormal perfusion in all patients (a), CK-MB over time according to normal or abnormal perfusion in all patients (b) and myoglobin
over time according to normal or abnormal perfusion in all patients (c).
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laboratory protocol [9–11]. Images were acquired by a phased-
array body surface coil during breath-holds and were electrocardio-
gram-triggered. Cine images (steady-state free precession sequence,
repetition time / echo time: 3.2 / 1.6 ms, ﬂip angle: 61 degrees,
matrix: 256×128, slice thickness: 6 mm, temporal resolution: 26 ms)
were acquired in 2-, 3-, 4-chamber views and every 1 cm in short-axis
views.
After cine images, 5 short-axis views and 2 long-axis views were
acquired every other beat for rest ﬁrst-pass perfusion imaging
(steady-state free precession sequence, inversion time: 110 ms,
repetition time / echo time: 190 / 1 ms, ﬂip angle: 49 degrees, matrix
128×72, in-plane spatial resolution 2.7×3.6 mm) after administering
0.1mmol/kg of gadolinium-diethylenetriaminepentaacetic acid (Mag-
nograf, Juste S.A.Q.F., Madrid, Spain) at a ﬂow rate of 3 ml/s.
Delayed enhancement imaging was performed in the same
projections used for cine images at least 10 minutes after adminis-
tering contrast. A segmented inversion recovery imaging with steady-
state free precession sequence was used (repetition time / echo time:
2.5 / 1.1 ms, slice thickness: 6 mm, ﬂip angle: 50 degrees, matrix:
195×192) nullifying myocardial signal.
CMR data analysis
CMR studies were analyzed by two experienced observers blinded
to all patient data using customized software (QMASSMR 6.1.5, Medis,
Leiden, The Netherlands). Segments locationwas deﬁned applying the
17-segment model [17].
Left ventricular end-diastolic and -systolic volumes (ml/m2),
ejection fraction (%) and mass (g/m2) were quantiﬁed by manual
deﬁnition of endocardial borders of all short-axis slices in cine-images.
Segmental abnormal perfusion was deﬁned, based on visual as-
sessment, as regions showing hypoenhancement both in short- and
long-axis views compared with remote non-infarcted segments in the
same slice at the end of ﬁrst-pass perfusion imaging [10,11]. A patient
was considered to have abnormal perfusion if N1 segment displayed
abnormal perfusion (Fig. 1).
Delayed enhancement was considered in case of signal intensity
N2 standard deviations with respect to a remote non-infarcted area in
delayed enhancement imaging. Infarct size was deﬁned as the
percentage of left ventricular mass showing delayed enhancement
[10].
Disagreement concerning abnormal perfusion occurred in 8 pa-
tients (5%) and was solved by consensus.
Statistical analysis
All data were tested for normal distribution using the one-sample
Kolmogorov-Smirnov test. Continuous data were expressed as the
mean±standard deviation and compared using Student's t-test. Group
percentages were compared using the chi-square test or Fisher's exact
test as appropriate. Nonparametric data were expressed as the median
with the interquartile range and were compared using the Mann-
Whitney U-test.
Receiver operating characteristic (ROC) curve analysis was used to
determine the accuracy of cardiac necrosis marker for predicting
abnormal perfusion.
Cardiac necrosis marker levels in the ﬁrst measurement after
reperfusion (at 6 hours) were most closely related to abnormal
perfusion. Attending to this ﬁnding as well as to the fact that, from a
clinical point of view, it is at this time point (soon after reperfusion)
when information on the microcirculatory status is most needed (e.g.
for assessment of the effect of therapies on microcirculation), our
analyses focused on necrosis markers at that time point.
The value of cardiac necrosis marker levels for predicting abnormal
perfusion was determined in the whole group and separately in the
thrombolysis and primary angioplasty group using a forward logistic
regression model, adjusted for variables yielding a p-value b .1 in
univariate analyses. Odds ratios and their 95% conﬁdence intervals
(OR [95% CI]) were computed.
Statistical signiﬁcance was considered for a two-tailed p-value
b .05. SPSS 13.0 (SPSS Inc, Chicago, Illinois, USA) was used.
Results
Temporal evolution of cardiac necrosis marker release and abnormal
perfusion
Out of 163 patients, 75 (46%) showed abnormal perfusion. Baseline
characteristics of the whole group and of patients with normal
and abnormal perfusion are displayed in Table 1. Patients with
abnormal perfusion had a higher heart rate, more anterior infarctions
and on angiography displayed a higher percentage of an occluded
infarct-related artery, abnormal TIMI ﬂow pre- angioplasty and
abnormal blush grade post-angioplasty. Patients treated with
primary and rescue angioplasty were more likely to have abnormal
perfusion.
Abnormal perfusion related to a larger release of all three cardiac
necrosis markers after reperfusion and higher peak values (Table 1,
Fig. 2). The most signiﬁcant differences were detected in all cases at
6 hours post-reperfusion. ROC curve analysis for detection of
abnormal perfusion of the 3 necrosis markers at 6 hours are displayed
in Table 2. Troponinwas the necrosis marker most strongly associated
with abnormal perfusion (Table 2, Figs. 2–4).
Patients were categorized according to the median troponin level
at 6 hours after reperfusion (lower troponin 0-42 ng/ml and high
troponin N42 ng/ml). Abnormal perfusion was more frequent in
patients with high troponin levels (50/81 (62%) vs. 25/82 (31%),
pb .0001).
On CMR imaging, patients with high troponin levels at 6 hours had
larger left ventricular volumes, a larger infarct size, poorer systolic
function and a wider perfusion deﬁcit (Table 3).
Patients treated with thrombolysis and primary angioplasty
In thrombolysis, abnormal perfusion was detected in 44 of 109
patients (40%) and was associated with a larger release of troponin
and CK-MB at 6-12 hours after thrombolysis and higher peak values.
There was a trend to a larger myoglobin release in patients with
abnormal perfusion (Fig. 3). In ROC curve analysis, troponin at 6 hours
yielded the largest area under the curve (Table 2). Abnormal perfusion
was more frequent in patients with high troponin levels after reper-
fusion (29/57 (51%) vs. 15/52 (31%), p=.019).
The relationship between abnormal perfusion and necrosis marker
release was even stronger in patients treated with primary
Table 2
Receiver operating characteristics curve analysis of cardiac necrosis markers for
detecting abnormal perfusion at 6 hours after revascularization in the whole group and
in the primary angioplasty and thrombolysis subgroup.
Area under the curve p-value 95% conﬁdence interval
Whole Group
Troponin .685 .00005 .603 - .767
Creatine kinase-MB .648 .001 .563 - .734
Myoglobin .580 .08 .490 - .669
Primary angioplasty
Troponin .787 .0003 .661 - .913
Creatine kinase-MB .764 .001 .632 - .897
Myoglobin .698 .01 .553 - .843
Thrombolysis
Troponin .647 .01 .543 - .750
Creatine Kinase-MB .612 .048 .501 - .723
Myoglobin .543 .4 .429 - .657
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angioplasty. Abnormal perfusion was detected in 31 of 54 patients
(57%) and was associated with a larger release of cardiac necrosis
markers after revascularization and higher peak values (Fig. 4). In ROC
curve analysis, troponin at 6 hours yielded the largest area under the
curve (Table 2). Abnormal perfusion was more frequent in patients
with high troponin levels at 6 hours after primary angioplasty (21/24
(88%) vs. 10/30 (33%), pb .0001). The time from revascularization to
CMR study did not differ between patients treated with primary
angioplasty and thrombolysis (9±5 days vs. 9±6, p=.9).
Multivariate analyses
For thewhole group and separately for the primary angioplasty and
thrombolysis subgroup, amultivariate analysis to identify predictors of
Fig. 3. Evolution of necrosis marker release depending on the presence of abnormal perfusion in patients treated with thrombolysis. Data at the bottom indicate the medianwith the
interquartile range of troponin over time according to normal or abnormal perfusion in patients treated with thrombolysis (a), CK-MB over time according to normal or abnormal
perfusion in patients treated with thrombolysis (b) and myoglobin over time according to normal or abnormal perfusion in patients treated with thrombolysis (c).
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abnormal perfusion, adjusted for variables showing a p-valueb .1 in the
univariate analysis, was performed (Table 4).
In the whole study group, high troponin levels at 6 hours after
reperfusion related to abnormal perfusion. Infarct size and vessel
occlusion prior to angioplasty were also associated with abnormal
perfusion. In patients treated with primary angioplasty, high troponin
levels at 6 hours were related to abnormal perfusion. Infarct size
and hypertension were also associated with abnormal perfusion. In
thrombolysis the predictors of abnormal perfusion were infarct size
and rescue angioplasty.
Independent association of troponin release with abnormal perfusion
regardless of infarct size or delayed presentation
Patients with elevated troponin at 6 hours after reperfusion
showed larger infarctions (Table 3). To verify that the association
Fig. 4. Evolution of necrosismarker release dependingon thepresenceof abnormal perfusion inpatients treatedwith primary angioplasty. Data at the bottom indicate themedianwith the
interquartile range of troponin over time according to normal or abnormal perfusion in patients treated with primary angioplasty (a), CK-MB over time according to normal or abnormal
perfusion in patients treated with primary angioplasty (b) and myoglobin over time according to normal or abnormal perfusion in patients treated with primary angioplasty (c).
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between troponin release and abnormal perfusion was not a mere
consequence of a larger infarct size or delayed presentation the fol-
lowing analyses were performed:
(a) The whole group was categorized according to the median of
infarct size (small infarct: ≤34% of left ventricular mass vs.
large infarct: N34% of left ventricular mass). Abnormal perfu-
sion was more frequent in patients with high troponin at
6 hours after reperfusion regardless of infarct size: small infarct,
13/31 (42%) vs. 9/50 (18%), p=.019; large infarct, 37/50 (74%)
vs. 16/32 (50%), p=.027.
(b) Upon arrival, 72 patients (44%) displayed normal troponin
values (b .1 ng/ml). As in the whole group, abnormal perfusion
was more frequent in the case of high troponin at 6 hours after
reperfusion: 19/35 (54%) vs. 11/37 (30%), p=.035.
(c) A multivariate analysis to identify predictors of high troponin
levels at 6 hours after reperfusion was performed including
variables showing a p-valueb .1 in the univariate analysis: heart
rate, anterior infarction, ST-segment resolution ≥70%, rescue
angioplasty, proximal left anterior descending lesion and all
CMR variables. Time to reperfusion was also included. Abnor-
mal perfusion (OR 1.23, 95%CI [1.03-1.48], per segment,
p=.021), ejection fraction (OR .96, 95%CI [.93-.1] per 1%
increase, p=.009) and ST-segment resolution ≥70% (OR 0.44
95%CI [.19-.99], p=.048) were predictors of high troponin
levels at 6 hours after reperfusion.
Discussion
The present study shows that in patients with reperfused STEMI, (1)
abnormal microvascular perfusion is associated with a larger release of
troponin, CK-MB and myoglobin. (2) In primary angioplasty this
relationship is more pronounced than in thrombolysis. (3) Serum levels
at 6 hours after reperfusion were most closely related to abnormal
perfusion. (4) Of the 3 necrosis markers, troponin best predicted abnor-
mal perfusion independent of infarct size and delayed presentation.
Abnormal perfusion after infarction
The paramount importance of microcirculation after myocardial
infarction has been known for over a decade [7,8]. CMR allows for a
complete non-invasive evaluation of patients after STEMI with
simultaneous and reliable assessment of heart chambers, infarct size
and microcirculation [9–11,14,15,18–20].
Using ﬁrst-pass perfusion CMR, we detected abnormal perfusion in
46% of patients. This ﬁgure is in agreement with recent reports [19]
and reﬂects the magnitude of the problem even in an ideal scenario
represented by patients with TIMI 3 ﬂow in the infarct-related artery
prior to the CMR study. Abnormal perfusion was not an incidental
ﬁnding, indeed it related to larger infarct sizes and left ventricular
volumes and to a more depressed systolic function. Furthermore,
several studies have shown that abnormal perfusion is associatedwith
a worse outcome [7,8,16].
Necrosis markers and abnormal perfusion
Studies from the past two decades demonstrated that successful
epicardial reperfusion relates to a larger release of cardiac necrosis
markers with a faster increase and wash-out [12,13,21,22]. Currently,
the conclusions of these works remain entirely valid, but in STEMI
attention has shifted from the macro- to the microcirculation [7,8]. At
the time of these studies, imaging modalities for assessment of
microvascular perfusion had not been well developed. Today, more
accurate instruments are available, meriting further investigation of
the association of cardiac necrosis marker release with microvascular
perfusion.
In this study, although each of the 3 necrosis markers showed a
relationship with abnormal perfusion, the association was strongest
with troponin.
In non-STEMI, adverse outcome of patients with elevated troponin
levels seems to result from the presence of ﬁssured plaques, coronary
thrombi and micro-embolization [5,6]. On the basis of this data one
could speculate that, at the microvascular level, high troponin
elevations relate to impaired rather than successful reperfusion. We
aimed to validate this hypothesis in the scenario of STEMI inwhich the
amount of necrosis and microvascular damage is much larger than in
non-STEMI.
Performing serial measurements of cardiac necrosis markers, we
found that patients showing abnormal perfusion on CMR imaging
displayed a signiﬁcantly larger release of necrosis markers with peak
values at around 6 hours after reperfusion. These results were
consistent in the whole group and separately in the thrombolysis
and primary angioplasty subgroup.
Interestingly, the differences in necrosis marker release between
patientswith normal and abnormal perfusionweremore pronounced in
primary angioplasty. Contrary to thrombolysis, where timing and
amount of epicardial ﬂow restoration is less clear, primary angioplasty
represents the perfect scenario to assess the relationship between
necrosis marker release and microcirculatory damage since TIMI 3 ﬂow
was completely and rapidly restored in all patients. In the adjusted
multivariate analysis, high troponin at 6 hours after successful
angioplastywas a strongpredictor of abnormalmicrovascular perfusion.
These ﬁndings likely reﬂect that in some patients, despite of full
recovery of TIMI 3 ﬂow in the epicardial artery, massive downstream
embolization provokes severe abnormal perfusion, large infarctions
and consequently higher elevations of necrosis markers.
Table 3
Cardiovascular magnetic resonance parameters according to the median troponin level
at 6 hours after reperfusion (lower troponin 0-42 ng/ml and high troponin N42 ng/ml).
Troponin
Lower n=82 High n=81 p-value
Ejection fraction (%) 57±12 46±13 b .0001
End-diastolic volume (ml/m2) 73±21 87±29 .001
End-systolic volume (ml/m2) 32±15 49±27 b .0001
Left ventricular mass (g/m2) 68±18 74±21 .06
Infarct size (% of left ventricular mass) 27±15 37±14 b .0001
Abnormal perfusion (segments) 1.2±1.7 3.1±2.8 b .0001
Table 4
Multivariate analysis for predictors of abnormal perfusion in the whole group and in the
primary angioplasty and thrombolysis subgroup.
Odds ratio 95% conﬁdence
interval
p-value
Whole group⁎
Troponin at 6 hours (Nmedian) 2.6 1.2 – 5.5 .012
Infarct size, per 1% of left ventricular mass 1.07 1.04 – 1.1 b .0001
Vessel occlusion prior to angioplasty 3.2 1.5 – 6.9 .003
Primary angioplasty†
Troponin at 6 hours (Nmedian) 13.9 2.4 – 78.8 .003
Infarct size, per 1% of left ventricular mass 1.1 1.03 – 1.2 b .0001
Hypertension 9.7 1.5 – 64.1 .02
Thrombolysis‡
Infarct size, per 1% of left ventricular mass 1.1 1.03 - 1.1 .001
Rescue angioplasty 6.7 1.8 - 24.5 .004
Adjusted for variables showing a p-valueb .1 in the univariate analysis.
⁎Heart rate, anterior infarction, primary and rescue angioplasty, time to reperfusion, ST-
segment resolution ≥70%, occluded infarct related artery pre-angioplasty, TIMI 3 ﬂow
pre-angioplasty, blush grade 2-3 post angioplasty, all 3 cardiac necrosis markers at
6 hours after reperfusion and all CMR parameters.
† Hypertension, anterior infarction, all 3 cardiac necrosis markers at 6 hours after
reperfusion and all CMR parameters.
‡ Anterior infarction, heart rate, rescue angioplasty, occluded artery pre-angioplasty
TIMI 3 ﬂow pre-angioplasty,blush grade 2-3 post-angioplasty , all 3 cardiac necrosis
markers at 6 hours after reperfusion and all CMR parameters.
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Troponin most closely related to abnormal perfusion, consistently
in the whole group, as well as in the subgroups treated with primary
angioplasty and thrombolysis. Additionally, a larger CK-MB and
myoglobin release also related to abnormal perfusion. Both markers
have been classically used for the detection of myocardial infarction
[23]. Myoglobin allows for a very early detection of myocardial
necrosis with limitations due to poor speciﬁcity. CK-MB, because of its
faster kinetics, is a traditional marker of reinfarction [24]. In the
present study, CK-MB and myoglobin levels follow the same course as
troponin values but in the multivariate analysis did not enter as
independent predictors of abnormal perfusion.
Elevated troponin and CK-MB after angioplasty yield prognostic
information and predict adverse outcome [25,26]. Our present study,
in the setting of reperfused STEMI, conﬁrms the link between elevated
biomarkers and abnormal perfusion previously described in non-
STEMI [27].
Independent association of troponin release with abnormal perfusion
The close relationship between troponin release and infarct size
has beenwell established [14]. Accordingly, we observed that patients
with higher troponin values displayed larger infarctions. Nevertheless,
abnormal perfusion was more frequent in patients with higher
troponin levels in smaller as well as in large infarctions, indicating
that the association of troponin release with abnormal perfusion was
not a mere consequence of infarct size. Moreover, in a multivariate
analysis adjusted for infarct size, the extent of abnormal perfusion on
CMR imaging persisted as an independent predictor of high serum
troponin levels.
Delayed presentation and consequently delayed reperfusion might
provoke larger infarcts and wider perfusion deﬁcits [2]. Thus, elevated
troponin levels detected in patients with abnormal perfusion might
originate from delayed reperfusion. Nevertheless, the association of
elevated troponin with abnormal perfusion persisted in patients
undergoing early reperfusion (with normal troponin values immedi-
ately before reperfusion) and was even stronger in patients with an
early and complete coronary ﬂow restoration via primary angioplasty,
suggesting a direct connection of abnormal perfusion with a larger
troponin release.
Limitations
The optimal time point to visualize microvascular obstruction has
not been deﬁned yet. Nevertheless, data derived from an experimental
dog model indicate that the extent of microvascular obstruction is
unchanged at 2 and 9 days after reperfused myocardial infarction [28].
Accordingly, several studies assessing the implications of microvascular
obstruction after STEMI have used theﬁrstweek (6-10 days) after STEMI
as the ideal moment for post-infarct imaging [19,29–31]. The mean
delay to CMR in our studywas9±6days (median8; IQR 6-10). A sooner
time point for assessing the extent of infarcted myocardium and
microvascular obstruction might overestimate these indices partly due
to extensive edema. On the other hand, CMR performed at a later time
point, might underestimate myocardial and microcirculatory damage.
Nonetheless, we cannot exclude changes in the extent of microvascular
obstruction during the days from STEMI to CMR imaging.
Conclusions
In reperfused STEMI, abnormal microvascular perfusion associates
with a larger release of cardiac necrosis markers. Troponin is the best
necrosis marker for predicting abnormal perfusion, especially in
primary angioplasty. Information yielded by troponin is greatest at
6 hours after reperfusion, a time point when information on the
microcirculatory status after reperfusion is most appreciated by the
clinician. The assessment of troponin serum levels at that time point
might serve as an additional diagnostic tool in our armamentarium to
identify patients with impaired microvascular perfusion.
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Background: Early stratiﬁcation of patients according to the risk for developing microvascular obstruction
(MVO) after ST-segment elevation myocardial infarction (STEMI) is desirable. We aimed to identify predic-
tors of cardiovascular magnetic resonance (CMR)-derived MVO from clinical+ECG, laboratory and angio-
graphic parameters available on admission.
Methods: Characteristics available on admission were documented in 97 STEMI patients referred for primary
angioplasty. MVO was determined using contrast-enhanced CMR.
Results: MVO was present in 44 patients (45%). The C-statistic for predicting MVO was: clinical+ECG (.832),
laboratory (.743), and angiographic parameters (.669). Adding laboratory to clinical+ECG information did
not improve the C-statistic (.873 vs. .832, p=.2). Further addition of angiographic data (.904) improved
the C-statistic of clinical+ECG (p=.04) but not of clinical+ECG and laboratory (p=.2). Independent pre-
dictors of MVO using clinical and ECG parameters were: Killip class N1 (OR 15.97 95%CI [1.37–186.76],
p=.03), diabetes (OR 6.15 95%CI [1.49–25.39], p=.01), age b55 years (OR 4.70 95%CI [1.56–14.17],
p=.006), sum of ST-segment elevation N10 mm (OR 4.5 95%CI [1.58–12.69], p=.005) and delayed presen-
tation N3 h (OR 3.80 95%CI [1.19–12.1], p=.02). A score was constructed assigning Killip class N1 2 points
and the remaining indexes 1 point. The incidence of MVO increased with the score: 0 point: 8.7%; 1 point:
28.1%; 2 points: 71.4%; and 3+ points: 93% (pb .0001).
Conclusions:MVO can be predicted using parameters already available on patient admission. We developed a
clinical-ECG score allowing for early and reliable classiﬁcation of STEMI patients according to the risk of MVO.
© 2011 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
In ST-segment elevation myocardial infarction (STEMI), despite
re-established epicardial blood ﬂow, perfusion at the microvascular
level may be impaired; a phenomenon referred to as microvascular
obstruction (MVO).
The capability of clinical parameters and biomarkers already avail-
able on patient admission for prediction of MVO has been barely
investigated so far. The prediction of MVO at such a pivotal time
point for therapeutic decision making has not been attempted before
and is desirable since it bears the potential of early risk stratiﬁcation
and might have therapeutic implications for therapies aiming at the
reduction of MVO before reperfusion therapy is initiated.
Cardiovascular magnetic resonance (CMR) allows for a compre-
hensive assessment of STEMI patients [1,2] with accurate detection
of MVO [3,4]. Several studies have shown that the presence of MVO
is associated with adverse outcome, unfavorable left ventricular
remodeling and higher mortality [5–7].
We hypothesized that characteristics available on admission would
be useful for early prediction of MVO-infarctions. For this purpose we
analyzed clinical, electrocardiographic, laboratory and angiographic
characteristics available on patient admission for determination of the
best and earliest predictors of MVO in patients with STEMI.
2. Materials and methods
2.1. Patients
We prospectively included 110 consecutive patients referred for primary percuta-
neous coronary intervention (PCI) for a ﬁrst STEMI within 12 h of chest pain onset.
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ST-elevation myocardial infarction was deﬁned following current deﬁnitions [8]. Pa-
tients with a history of prior myocardial infarction or new onset bundle branch block
were not considered for participation. The inclusion criteria were: stable clinical course
without complications during hospitalization and no contraindications to CMR. We
excluded 13 patients because of death (n=5), reinfarction (n=2), clinical instability
(n=3) and claustrophobia (n=3). Therefore, the ﬁnal study group comprised 97
patients. All patients gave written informed consent and the study protocol was
approved by the institutional committee on human research and conforms to the eth-
ical guidelines of the 1975 Declaration of Helsinki.
2.2. Clinical and ECG characteristics
Clinical characteristics were recorded in all cases on patient admission. Time from
pain onset to presentation was recorded. Delayed presentation was considered as N3 h
[9]. Killip class was determined [10]. The TIMI risk score for each patient was calculated
[11].
A standard 12 lead ECG was recorded upon admission at a paper speed of 25 mm/s
and an ampliﬁcation of 10 mm/mV. The isoelectric line was deﬁned as the level of the
TP-segment. Extent of ST-elevation was measured 20 ms after the J-point in every lead
and the sum of ST-elevation (sumSTE) was calculated in leads V1–6, I, and aVL for
anterior infarction and in leads II, III, aVF, V5, and V6 for non-anterior infarction
using previously validated algorithms [12–14]. Infarct location was assigned as anteri-
or versus non-anterior infarction. Residual sum of ST-segment elevation 90 min after
PCI was determined.
2.3. Laboratory test
Troponin I (using a highly sensitive immunoassay, Dimension, Dade Behring Inc.,
Newark, USA) CK-MB mass and myoglobin (using immunometric assay; DPC; Los
Angeles, CA, USA) were determined. Troponin I was serially measured at 6, 12, 24, 48
and 96 h after reperfusion. Peak troponin I was determined.
The coefﬁcient of variation for troponin values between 0.1 and 1 ng/ml was b10%
and for troponin values N1 ng/ml was b5%. The coefﬁcients of variation for CK-MB
mass N5 ng/ml and for myoglobin N70 ng/ml were b10%.
Total leucocyte count and separately neutrophil, lymphocyte and monocyte count
(all as ×1000 cells/ml) were determined by an automated blood cell counter.
2.4. Coronary angiography and PCI
PCI was performed within 12 h of symptom onset in all patients. Door to balloon
time was recorded. TIMI ﬂow grade [15] before and after PCI was assessed. Myocardial
blush grade [16] and corrected TIMI frame count [17] were evaluated after PCI. Patients
were treated with double anti-platelet therapy except of 9 patients who received
mono-therapy with aspirin after balloon angioplasty only with good angiographic
result. Patients with contraindication to dual antiplatelet therapy (chronic or active
bleeding (n=5), aspirin intolerance, (n=2) or oral anticoagulation due to paroxysmal
atrial ﬁbrillation (n=1)) treated with stenting received indeﬁnite clopidogrel and
low-molecular weight heparin for up to 1 month. Angiographic data was analyzed by
an experienced investigator using standard software blinded to CMR results
(HM3000, Philipps, Best, The Netherlands).
2.5. Cardiovascular magnetic resonance imaging
CMR (1.5-T scanner, Sonata Magnetom, Siemens, Erlangen, Germany) was per-
formed at least 48 h after PCI in accordance with our laboratory protocol [18,19]. Im-
ages were acquired by a phased-array body surface coil during breath-holds and
were ECG-triggered. Cine images (true fast imaging with steady state precession, rep-
etition time/echo time: 3.2/1.6 ms, ﬂip angle: 61°, matrix: 256×128, slice thickness:
6 mm, temporal resolution: 26 ms) were acquired in 2-, 3-, and 4-chamber views
and every 1 cm in short-axis views.
Late enhancement imaging was performed in the same projections used
for cine images at least 10 min after administering 0.1 mmol/kg of gadolinium-
diethylenetriaminepentaacetic acid (Magnograf, Juste S.A.Q.F., Madrid, Spain). A seg-
mented inversion recovery true fast imaging with steady state precession sequence was
used (repetition time/echo time: 2.5/1.1 ms, slice thickness: 6 mm, ﬂip angle: 50°,matrix:
195×192) nullifying myocardial signal.
2.6. CMR data analysis
CMR studies were analyzed by an experienced observer blinded to all clinical, ECG,
laboratory and angiographic data using customized software (QMASS MR 6.1.5, Medis,
Leiden, The Netherlands).
Segment location was deﬁned according to the 17-segment model [20]. Left
ventricular mass (g/m2), ejection fraction (%) and volumes (ml/m2) were quantiﬁed
by manual deﬁnition of endocardial borders of all short-axis slices in cine-images.
Late enhancement was considered in the case of signal intensity N2 standard devia-
tions with respect to a remote non-infarcted area in late enhancement imaging
[18,21]. Infarct size was calculated as the percentage of left ventricular mass showing
late enhancement [19].
According to our laboratory protocol [22], the presence of MVO was semi-quanti-
tatively deﬁned as a lack of contrast uptake in the core of at least one segment sur-
rounded by tissue showing late enhancement [3] (see Fig. 1). In our laboratory,
intra-observer variability for the detection of MVO using this criterion is less than 5%
[23].
2.7. Statistical analysis
All data were tested for normal distribution using the one-sample Kolmogorov–
Smirnov test. Continuous normally distributed data were expressed as the mean±
standard deviation and compared using the Student's t-test. Non-parametric data
were expressed as the median with the interquartile range and were compared with
the Mann–Whitney U-test. Group percentages were compared using the chi-square
test or Fisher's exact test where appropriate.
The individual predictive capability of clinical and ECG, laboratory and angiograph-
ic parameters was assessed by calculating the C-statistic derived from logistic regres-
sion analysis including all variables yielding a pb .2 in univariate analysis. In detail
the variables included were: for clinical and ECG characteristics age, diabetes, systolic
blood pressure, current smoker, delayed presentation, Killip classN1, sumSTE and
infarct location. For laboratory parameters: CK-MB, myoglobin, leucocytes, neutrophils
and lymphocytes. For angiographic parameters: involvement of the proximal left
anterior descending artery, vessel occlusion prior to angioplasty and TIMI 3 ﬂow
post-angioplasty yielded a p-valueb .2 and were included. Moreover, from a patho-
physiological point of view, TIMI 3 ﬂow pre-angioplasty was also included.
In order to assess the incremental predictive capability of parameters in the order
of temporal availability to the clinician on patient admission, the C-statistics of 3 multi-
variable models (model 1: only clinical and ECG variables; model 2: clinical and ECG+
laboratory variables; model 3: clinical and ECG+laboratory+angiographic variables)
were calculated and compared using Rocomp module (STATA 11.0). Brieﬂy, for each
curve, Roccomp reports summary statistics and provides a test for the equality of
the area under the curves, using an algorithm suggested by DeLong, DeLong, and
Clarke-Pearson.
In order to identify independent predictors of MVO, a logistic regression analysis
was performed including variables yielding a p-valueb .2 in univariate analysis. Contin-
uous variables were dichotomized according to cut-off values established on the basis
of their area under the receiver operating characteristic curves for predicting MVO by
maximizing the observed overall diagnostic accuracy (minimizing the number of false
positives plus the number of false negatives). Odds ratios (OR) and their respective 95%
conﬁdence intervals (95%CI) were computed.
Statistical signiﬁcance was considered for two-tailed p-valueb .05. SPSS 13.0 (SPSS
Inc, Chicago, Illinois, USA) and STATA 11.0 (StataCorp, College Station, Texas, USA)
were used.
3. Results
The baseline clinical, ECG, laboratory and angiographic character-
istics of all patients are displayed in Table 1. The majority of the
patients was male (79%) with a mean age of 60±14 years. The
median time from pain onset to presentation was 115 [61–240]min.
Median door to balloon time was 79 [44–123]min. All patients under-
went primary PCI with stent placement or balloon angioplasty in 92%
of the cases. In 8 patients, revascularization was not performed due to
failed angioplasty (n=5) or because of TIMI 3 ﬂow on angiography
Fig. 1. Example of late enhancement imaging of MVO. Short-axis view of late enhance-
ment imaging in two patients with anterior infarction of comparable size. Left: Normal
contrast uptake in the infarcted zone. Right: Lack of contrast uptake in the core of the
infarcted area indicating microvascular obstruction (arrow).
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in the absence of a signiﬁcant stenosis (n=3). The in-hospital medi-
cation of the patient population is displayed in Table 2. Patients with
MVO received less beta-blocker therapy (34% vs. 60%, p=.01).
3.1. Cardiovascular magnetic resonance imaging results
CMR was performed 8±5 days after PCI. MVO was present in 44
patients (45%). Patients with MVO-infarctions had a lower left ven-
tricular ejection fraction (43%±12 vs. 59±11, pb .0001), a larger
infarct size (37%±22 vs. 11±10, pb .0001) andmore dilated left ven-
tricular volumes and masses. CMR results are displayed in Table 3.
3.2. Individual value of parameters on patient admission for predicting
MVO
Clinical and ECG characteristics on admission andMVO. Clinical vari-
ables on admission associated with MVO were: younger age (56±13
vs. 60±13, p=.008), lower systolic blood pressure (120 mm Hg±25
vs. 132±25, p=.02), diabetes (25% vs. 9%, p=.04) and Killip classN1
(23% vs. 2%, p=.002). There was a trend towards a higher rate of
delayed presentation (N3 h from pain onset) in patients with MVO-
infarctions (39% vs. 21%, p=.05) The ECG on admission revealed a
higher percentage of anterior infarctions (68% vs. 34%, pb .0001) and a
larger median sumSTE (12 mm [7–17] vs. 6 [4.5–10], pb .0001) in pa-
tients with MVO infarctions. The C-statistic for predicting MVO of clini-
cal and ECG variables on admission was .832 [.742–.901].
Table 1
Baseline, electrocardiographic, laboratory and angiographic characteristics of all patients and of patients with and without MVO.
All patients n=97 MVO−n=53 MVO+n=44 p-value
Clinical
Age (years) 60±14 60±13 56±13 .008
Male sex (%) 77 (79) 41 (77) 36 (82) .6
Diabetes (%) 16 (17) 5 (9) 11 (25) .04
Hypertension (%) 47 (49) 26 (49) 21 (48) .9
Hypercholesterolemia (%) 40 (41) 20 (38) 20 (46) .4
Previous coronary artery disease (%) 10 (10) 5 (9) 5 (11) .8
Current smoker (%) 52 (54) 24 (45) 28 (64) .07
Heart rate (bpm) 80±17 79±16 81±18 .6
Systolic blood pressure (mm Hg) 126±25 132±25 120±25 .02
Delayed presentation (N3 h) 28 (29) 11 (21) 17 (39) .05
Killip class N1 11 (12) 1 (2) 10 (23) .002
ECG
Anterior infarction (%) 48 (50) 18 (34) 30 (68) b.0001
Median sum of ST-segment elevation on admission (mm) 9 [6–14] 6 [4.5–10] 12 [7–17] b.0001
Median sum of ST-segment elevation 90 min post PCI (mm) 3 [0–7] 2 [0–6] 6 [2–9] .001
Laboratory
Median troponin on admission (ng/ml) .14 [.04–3.19] .13 [.05–.59] .18 [.01–20.0] .4
Median creatine kinase MB on admission (ng/ml) 2.4 [1.0–55.0] 2 [1.1–6.0] 6 [1.0–187] .1
Median myoglobin on admission (ng/ml) 69 [31–162] 55 [23–99] 95 [45–899] .003
White blood cell count on admission (×1000 cells/ml) 12.3±3.9 11.7±4.0 13.0±3.8 .1
Neutrophil count on admission (×1000 cells/ml) 9.1±3.8 8.4±3.7 10.1±3.7 .03
Lymphocyte count on admission (×1000 cells/ml) 2.2±1.4 2.4±1.2 2.0±1.2 .1
Monocyte count on admission (×1000 cells/ml) .55±.22 .52±.19 .58±.26 .2
Median peak troponin (ng/ml) 56 [23–95] 31 [17–54] 95 [77–124] b.0001
Angiography
Median door to balloon time (min) 79 [44–123] 77 [45–118] 80 [43–134] .7
Proximal left anterior descending artery (%) 28 (29) 9 (17) 19 (43) .005
Vessel occlusion prior to angioplasty (%) 74 (76) 37 (70) 37 (84) .1
Stent/balloon angioplasty (%) 89 (92) 48 (91) 41 (93) .6
TIMI 3 ﬂow pre-angioplasty (%) 12 (12) 7 (13) 5 (11) .8
TIMI 3 ﬂow post-angioplasty (%) 88 (91) 50 (94) 38 (86) .2
Final myocardial blush grade 2–3 (%) 68 (72) 37 (73) 31 (71) .8
Median corrected TIMI frame count 14 [11–19] 13 [11–17] 14 [12–20] .7
MVO = microvascular obstruction, TIMI = thrombolysis in myocardial infarction.
Table 2
Inhospital medication of all patients and according to the presence of MVO.
All patients
n=97
MVO−n=53 MVO+n=44 p-value
Mono antiplatelet
therapy (%)
97 (100) 53 (100) 44 (100) .9
Dual antiplatelet
therapy (%)
72 (74) 39 (74) 33 (75) .9
ACE inhibitors (%) 37 (38) 16 (30) 21 (48) .08
AT-II receptor blockers (%) 21 (22) 15 (28) 6 (14) .08
Beta blockers (%) 47 (49) 32 (60) 15 (34) .01
Statins (%) 66 (68) 37 (70) 29 (66) .7
Diuretics (%) 14 (13) 7 (13) 7 (16) .7
MVO=microvascular obstruction, ACE=angiotensin converting enzyme, AT=angiotensin.
Table 3
CMR characteristics of all patients and according to the presence of MVO.
All patients
n=97
MVO−n=53 MVO+n=44 p-value
Ejection fraction (%) 52±14 59±11 43±12 b.0001
End-diastolic volume
index (ml/m2)
81±28 71±19 94±32 b.0001
End-systolic volume
index (ml/m2)
41±26 27±14 55±29 b.0001
Left ventricular mass
(g/m2)
73±18 66±14 81±19 b.0001
Infarct size (%) 23±21 11±10 37±22 b.0001
MVO = microvascular obstruction.
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Laboratory ﬁndings on admission and MVO. Laboratory ﬁndings
on admission associated with MVO were: higher myoglobin serum
levels (95 ng/ml [45–899] vs. 55 [23–99], p=.003) and higher neu-
trophil count (10.1 (×1000 cells/ml) ±3.7 vs. 8.4±3.7, p=.03).
The C-statistic for predicting MVO of laboratory ﬁndings on admission
was .743 [.643–.826].
Angiographic parameters and MVO. The only angiographic param-
eter signiﬁcantly associated with MVO was involvement of the prox-
imal left anterior descending artery (43% vs. 17%, p=.005). The C-
statistic for predicting MVO of angiographic variables was .669
[.566–.762]. Clinical, ECG, laboratory and angiographic variables
according to the presence of MVO are displayed in Table 1. The
C-statistics are displayed in Fig. 2.
3.3. Incremental value of parameters on patient admission for predicting
MVO
The incremental value of parameters for predicting MVO in the
order of temporal availability was analyzed. The C-statistic of clinical
and ECG characteristics (model 1) did not improve signiﬁcantly after
adding laboratory information (model 2) (.873 [.789–.932] vs. .832
[.742–.901], p=.2). Further addition of angiographic ﬁndings
(model 3: 904 [.827–.955]) signiﬁcantly improved the C-statistic
compared to model 1 (p=.04) but not compared to model 2
(p=.2) (Fig. 3).
3.4. Predictors of MVO on admission
Clinical and ECG characteristics, the parameters most timely avail-
able on patient admission, displayed a high predictive value for MVO
which was only signiﬁcantly improved by the addition of both labora-
tory and angiographic data. Owing to this ﬁnding, a multivariate anal-
ysis to identify predictors of MVO from clinical and ECG parameters
was performed. Independent predictors of MVO were: Killip classN1
(OR 15.97 95%CI [1.37–186.76], p=.03), diabetes (OR 6.15 95%CI
[1.49–25.39], p=.01), age b55 years (OR 4.70 95%CI [1.56–14.17],
p=.006), sumSTEN10 mm (OR 4.5 95%CI [1.58–12.69], p=.005)
and delayed presentation (OR 3.80 95%CI [1.19–12.1], p=.02). Low
blood pressure on admission was not included in this analysis since
Killip class already accounts for cardiogenic shock. The C-statistic
for predicting MVO of the model using these variables was .846
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Fig. 2. Individual diagnostic value of each domain for predicting MVO. The C-statistic of clinical and ECG data includes: age, diabetes, hypercholesterolemia, smoker, delayed pre-
sentation, Killip classN1, sum of ST-segment elevation and infarct location. The C-statistic of laboratory data includes: CK-MB, myoglobin, leucocytes, neutrophils and lymphocytes.
C-statistic of angiographic variables includes: involvement of the proximal left anterior descending artery, vessel occlusion prior to angioplasty and TIMI 3 ﬂow post-angioplasty.
Moreover, from a pathophysiological point of view, TIMI 3 ﬂow pre-angioplasty was also included.
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Fig. 3. Incremental diagnostic value of combined domains for predicting MVO. Model 1 = clinical and ECG characteristics. Model 2 = clinical and ECG characteristics+laboratory
data. Model 3 = clinical and ECG characteristics+laboratory+angiographic data.
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[.758–.912] which was not inferior to any of the 3 models (p-value
between .2 and .8).
3.5. Development of a predictive score
According to the ORs obtained we created a 4 level score depend-
ing on the presence of each index. Killip classN1 was assigned 2
points and the remaining indexes 1 point. The sum was calculated
for each patient and patients were categorized into 4 groups (0
points, 1 point, 2 points and 3+ points). The C-statistic for predicting
MVO using this score was 0.845 [0.756–0.911] which was not inferior
to any of the 3 models (p-value between .1 and .9). The incidence of
MVO gradually increased as the score increased: 0 points: 2 of 23
(8.7%); 1 point: 9 of 32 (28.1%); 2 points: 20 of 28 (71.4%) and 3+
points: 13 of 14 (93%) (pb .0001 for the trend, Fig. 4). In parallel,
the extent of MVO (number of segment with MVO) gradually in-
creased with each step of the score (p for the trendb .0001, Fig. 5).
3.6. Comparison of the predictive score with other markers of MVO
Patients with MVO infarctions had a higher TIMI risk score than
patients without MVO (3.3±2.2 vs. 2.2±1.9, p=.004), nevertheless
the C-statistic of the TIMI risk score to predict MVO was signiﬁcantly
lower compared to the newly developed score (.658 vs. .839, p=.004).
The C-statistic of the newly developed score was compared with
other, less timely available, markers of MVO, namely peak troponin
and residual ST-segment elevation. Additionally, the score was com-
pared to angiographic surrogates of MVO after PCI: TIMI ﬂow grade,
corrected TIMI frame count and myocardial blush grade (Fig. 6). The
newly developed score performed comparable to peak troponin
(p=.6) and was superior to residual ST-elevation (p=.01) and any
of the angioghraphic parameters (pb .01).
4. Discussion
This study analyzes the individual and incremental value of
parameters available on patient admission, namely clinical and ECG,
laboratory and angiographic characteristics, in the order of availabili-
ty for predicting CMR derived-MVO in STEMI. It shows that clinical
and ECG characteristics, the two diagnostic domains most rapidly
available on patient admission, yield a high predictive value for
MVOwhich is only signiﬁcantly improved by the addition of both lab-
oratory and angiographic ﬁndings. We created a stepwise score using
independent predictors from clinical and ECG characteristics. Using
this score it was possible to classify patients according to the preva-
lence and extent of MVO after STEMI.
4.1. Microvascular obstruction
Despite restored epicardial blood ﬂow in STEMI, MVO occurs in
about 40% of the cases [24,25]. CMR has become the gold standard
in cardiovascular imaging allowing for a comprehensive assessment
of a wide range of parameters in patients with STEMI [1], including
infarct size and MVO [3,4]. Several studies have shown that the pres-
ence of MVO is associated with worse outcome and left ventricular
remodeling compared to non-MVO infarctions. [3,24–26]. Timely
detection of MVO is desirable since it potentially allows for early
risk stratiﬁcation and bears potential therapeutic implication for
future therapies aiming at the reduction of MVO.
4.1. Clinical characteristics on admission and MVO
Data on how patients with MVO-infarctions initially present is
scarce since most studies have focused on prediction of MVO after
reperfusion therapy and the prognostic impact of MVO. We deter-
mined the individual value of baseline characteristics in the order as
they are available on patient admission and the incremental value
for predicting CMR-derived MVO in a large cohort of STEMI patients
referred for primary PCI. An interesting ﬁnding is that clinical charac-
teristics alone exhibited a high predictive value. This predictive capa-
bility was only signiﬁcantly improved using the combination of all
diagnostic domains. Of these clinical parameters, Killip class was
identiﬁed as strongest predictor of MVO. In our cohort only one
patient with Killip class N1 on admission did not develop MVO.
High Killip class has been shown to be an independent predictor of
failure to restore TIMI 3 ﬂow in the epicardial coronary artery after
STEMI [27]. In our study we did not conﬁrm this ﬁnding (TIMI 3
ﬂow in patients with Killip N1: 82%), but there was a strong associa-
tion with the development of MVO. This ﬁnding might partly explain
the worse prognosis of patients with a high Killip class by linking it to
the development of MVO which in turn exhibits a strong negative
impact on prognosis [3,22].
Patients with MVO-infarction were younger and there was a trend
towards delayed presentation. The observation that young age associ-
ates with MVO has not been reported before. Smaller studies did not
show a signiﬁcant age difference between patients with MVO and
non-MVO-infarctions [7]. A possible explanation for this ﬁnding is
that younger patients might have less ischemic preconditioning and
less collaterals than older patients aggravating myocardial damage
by a total coronary occlusion.
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Fig. 4. Prevalence of MVO at each step of the score. Abbreviations: MVO=microvascular
obstruction, sumSTE = sum of ST-segment elevation.
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Fig. 5. Extent (number of segments) of MVO at each step of the score. Abbreviations:
MVO = microvascular obstruction.
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Patients who developed MVO-infarctions had a trend to a higher
rate of delayed presentation. This ﬁnding is in line with previous
studies demonstrating that MVO strongly depends on the duration
of the ischemic time [28,29].
There was a signiﬁcant lower percentage of beta-blocker use in
patients with MVO. Additionally there was a trend to more ACE-
Inhibitor and less AT-II receptor blocker use in patients with MVO.
Data on in-hospital medication is difﬁcult to interpret because these
data might be subject to several confounders.Whether this observation
is linked to the pathophysiology of MVO or merely an epiphenomenon
(cause or consequence) cannot be determined. Patients with MVO
tended to have larger myocardial infarctions leading to more hemody-
namic compromise which might have precluded the use of beta
blockers. The present data is observational, not randomized and subject
to confounding factors and should be interpreted with care.
4.2. Biomarkers of MVO
The association of CMR-derived MVO with biomarkers like the
ECG, cardiac necrosis markers and leucocytes has been investigated
in the past. Of ECG parameters, the amount of residual sumSTE after
successful primary PCI is a strong predictor of MVO and also predicts
myocardial salvage [30–32]. The present study demonstrates a high
predictive value of ECG data for MVO already on admission.
After successfully reperfused STEMI a larger release of cardiac ne-
crosis markers, especially troponin, is associated with MVO [33–35].
Since troponin values can be normal or low on admission in STEMI,
there was no signiﬁcant association with MVO in the present study.
Due to its faster kinetics, myoglobin was signiﬁcantly higher in pa-
tients developing MVO-infarctions. Nevertheless, the use of bio-
markers for early risk stratiﬁcation and decision making can be
limited due to the time delay implied in their use.
Finally, post-interventional lymphopenia has been linked to a
larger amount of MVO in reperfused STEMI [36]. The present study
shows that on admission, there is only a trend towards a lower lym-
phocyte count in patients with MVO infarctions, but neutrophil
count was signiﬁcantly higher.
4.3. Angiographic parameters and MVO
Angiographic parameters have been used in the past for the eval-
uation of microvascular reperfusion in STEMI.
In our study, the only angiographic parameter signiﬁcantly associ-
ated with MVO was involvement of the proximal left anterior
descending artery. The lack of association of established angiographic
parameters like TIMI ﬂow grade, frame count or myocardial blush
grade might be owed to several reasons. Firstly, the evaluation of the
microcirculation by angiography is performed at a very early time
point and it has been shown that the microcirculation displays a
dynamic behavior in the ﬁrst week after STEMI [18]. Re-established
epicardial blood ﬂow, represented by TIMI 3 ﬂow, is a very speciﬁc
but not very sensitive marker for successful microvascular reperfu-
sion. Accordingly, in our study TIMI 3 ﬂow was achieved in 91% of
patients and there was not a statistical associationwithMVO.Myocar-
dial blush grade is a good alternative for evaluating microvascular
perfusion, nevertheless this index displays a high interobserver vari-
ability. Lastly and a limitation of our study, the evaluation of angio-
graphic parameters in a core laboratory might have yielded better
results. The addition of both laboratory and angiographic parameters
to clinical and ECG characteristics improved the predictive capacity
of themodel, nevertheless the usefulness of angiography for early pre-
diction of MVO is limited because the information arrives relatively
late for clinical decision making.
4.4. Prediction of MVO on admission
The present study is the ﬁrst to address the problem of MVO in
patients with STEMI before reperfusion therapy is initiated. A com-
mon trait of previous studies investigating predictors of MVO is,
that they were focused on parameters obtained after the therapeutic
intervention had been carried out. At that time point the microvascu-
lar damage might not be inﬂuenceable to the same degree as it could
be with the use of earlier predictors. We identiﬁed, from a wide range
of clinical and ECG, laboratory and angiographic data available on pa-
tient admission independent predictors of MVO. We detected that
clinical characteristics and ECG data, the two diagnostic domains
most rapidly available to the clinician on patient admission, yielded
a predictive value that was only improved by the addition of both lab-
oratory and angiographic parameters. In order to facilitate integration
of this ﬁnding into clinical practice we devised a simple predictive
score according to the presence of 5 indexes (Killip class N1,
ageb55, diabetes, delayed presentation and sumSTEN10 mm). This
score allowed for classiﬁcation of patients according to the risk for
developing MVO after reperfusion therapy. The prevalence, ranging
from low (8.7%) to high risk (93%), as well as the extent of MVO grad-
ually increased as the score increased.
Potentially this score, using simple, early and universally available
parameters, allows for triage of patients according to the risk of MVO
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Fig. 6. Comparison of the predictive score with other markers of MVO. Abbreviations: MVO=microvascular obstruction, sumSTE = sum of ST-segment elevation, TIMI = thrombolysis
in myocardial infarction.
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and might prove useful as a tool for assessing the efﬁcacy of future
early therapies aiming at the reduction of MVO.
4.5. Limitations
This study represents the discovery group for this predictive score,
and although derived from a large population of STEMI patients trea-
ted with primary PCI, further prospective validation in order to deter-
mine the true value of the clinical and therapeutic implications of
these results is warranted.
ECGs were recorded at a paper speed of 25 mm/s. We cannot
exclude that using a speed of 50 mm/s would yield a higher diagnos-
tic accuracy for MVO.
The optimal time point to visualize MVO has not been deﬁned yet.
Nevertheless, data derived from an experimental dog model indicate
that the extent of microvascular obstruction is unchanged at 2 and
9 days after reperfused myocardial infarction [37]. Accordingly, sev-
eral studies assessing the implications of MVO after STEMI have
used the ﬁrst week (6–10 days) after STEMI as the ideal moment for
post-infarct imaging [3,7,24,38]. The mean delay to CMR in our
study was 8±5 days. A sooner time point for assessing the extent
of infarcted myocardium and MVO might overestimate these indices
partly due to extensive edema. On the other hand, CMR performed
at a later time point, might underestimate myocardial and microcir-
culatory damage. In our cohort, there was no signiﬁcant difference
in the mean delay (days) to CMR and the presence of MVO (MVO
absent: 7 days [5–9.5] vs. MVO present 6 [5–9], p=.1). Nonetheless,
we cannot exclude changes in the extent of MVO during the days
from STEMI to CMR imaging.
In the present study, we did not routinely record pre-hospital med-
ication and the occurrence of pre-infarct angina accounting for a possi-
ble ischemic preconditioning. Also the use of GpIIb/IIIa inhibitors was
left at the discretion of the interventional cardiologist. In total GpIIb/IIIa
inhibitors were used in 59 patients (61%). There was no statistical
difference in the occurrence of MVO according to the use of GpIIb/IIIa
inhibitors (MVO+71% vs. MVO−53%, p=.08), albeit with a contrain-
tuitive trend towards a higher occurrence ofMVOusingGpIIb/IIIa inhib-
itors. Since this study was not designed to address the impact of pre-
hospital and/or adjunctive pharmacotherapy on the incidence of MVO,
further investigation on this issue is clearly warranted.
5. Conclusions
The prevalence of MVO after STEMI can be predicted using param-
eters available on patient admission. Clinical characteristics and ECG
parameters yield a high predictive value which was only improved
by the addition of both laboratory and angiographic ﬁndings. We
developed a score using clinical and ECG characteristics allowing for
classiﬁcation of STEMI patients according to the prevalence and
extent of MVO. Given the timely availability this score might prove
useful for early classiﬁcation and risk stratiﬁcation before reperfusion
therapy is initiated and for assessing the value of future therapies
aiming at the reduction of MVO in STEMI.
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